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1 INTRODUCTION  
1.1  TUMOR PATHOLOGY  
 
Cancer is the second leading cause of death globally, with an estimation of  10 million deaths in 
2020 meaning that 1 in 6 deaths is due to cancer as reported by the World Health Organization 
(WHO)[1].  Several hypothesis suggest that the development of human tumor start with a single 
mutation in a normal cell that acquires new biological capability and selective growth propensity 
over other cells. The proliferation of the mutated cells leads to progressive evolution and sequential 
selection of sublines that show increasingly abnormal behavior leading to a tumor formation.[2] 
Hanahan and Weinberg, in 2000 defined six hallmark of cancer for rationalizing the complex 
disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell 
death, enabling replicative immortality, inducing angiogenesis,  activating invasion and 
metastasis[3]. Typically,  most of the  numerous genomic mutations are on  genes encoding 
Proteins involved in cellular processes such as DNA replication, DNA repair, cell cycle 
progression that maintain cellular homeostasis. Therefore, alteration of any of these homeostatic 
processes could entrain cells to the progressive genomic instability and phenotypic evolution 
characteristic of carcinogenesis[4]. Usually, the normal tissue architecture and function are 
controlled by the release of growth-promoting signals that ensure the homeostasis of cell number 
through the cell growth-and-division cycle. Those signals are transmitted by growth factors that 
bind cell-surface receptors that proceed to emit signals influencing yet other cell-biological 
properties, such as cell survival and energy metabolism. The loss of normal guard against genomic 
mutation and the consequent instability of the genomic information  leads to a progressive 





1.2 BREAST CANCER  
 
Breast cancer  is the most common malignancy in females and the second leading cause of cancer 
related deaths with an incidence of >1,000,000 cases occurring worldwide annually as reported by 
the International Agency for Research on Cancer (IARC)[5].  
Breast cancer is a heterogeneous disease that exhibits numerous morphological features, different 
immune-histochemical profiles and unique histopathological subtypes that have specific clinical 
behavior [6]. By definition, adenocarcinomas are the malignant tumors that originate in mammary 
epithelial layer and specifically in the inner lining epithelium of the ducts (ductal carcinoma) and 
lobules that supply the ducts with milk (lobular carcinoma). Based on the grade of proliferation 
and status of the disease, the tumor could be defined “in situ carcinoma” when limited to the 
epithelial component of the breast, or “invasive carcinoma” when invade the stroma.[7, 8] Among 
the complexity of the histological characterization, pathologists have identified some specific 
architectural and cytological patterns that are defined “histological special types” because they 
consistently associate with distinctive clinical behavior. They include not more than 25% of all 
breast cancers, all the other are classified as “invasive ductal carcinomas not otherwise specified” 
(IDC-NOS) that do not exhibit sufficient characteristic to be inserted in the special type Table 1 
[8-10]. Despite the histopathological analysis provide a knowledge about the histological grade 
and type of the tumor, they are not enough in deciding the therapy . [11, 12],  
Over the past decades, the complexity of the disease has been investigated using molecular 
technique leading to refining of the molecular characterization based on the gene expression[7]. 





that underlie some biological proprieties such as metastatic behavior or histological grade that help 
to identify signatures associated with prognosis and response to therapy[13].  
 






Currently, clinical practice typically uses a surrogate classification of five subtypes on the basis of 
histological and molecular characteristics Figure 1 [14].  The intrinsic molecular classification of 
Perou and Sorlie, reported in 2000, are based on a 50- gene expression signatures and established 
four subtypes of breast cancer based on the expression of endocrine receptors (estrogen and 
progesterone receptor ER) and the aberrant expression of human epithelium growth factor 
(HER2+)[15].  
 
Figure 1.1: Breast cancer. The histological subtypes described here (top right) are the most 
frequent subtypes of breast cancer; ductal carcinoma (now referred to as ‘no special type’ (NST)) 
and lobular carcinoma are the invasive lesions; their pre-invasive counterparts are ductal 





intrinsic subtypes are typically used clinically and are based on histology and 
immunohistochemistry expression of key proteins: estrogen receptor (ER), progesterone receptor 
(PR), human epidermal growth factor receptor 2 (HER2) and the proliferation marker Ki67. 
Tumours expressing ER and/or PR are termed ‘hormone receptor- positive’; tumours not 
expressing ER, PR and HER2 are called ‘triple- negative’.  
 
The molecular subgroup includes: i) luminal type (expressing the estrogen receptor (ER)); ii) 
basal- like (include explanation of the characteristic); iii) human epidermal growth factor enriched 
(overexpressed receptor HER2, without ER expression); normal type. The luminal type incudes 
roughly the 70% of the invasive breast cancer. Based on the expression of HER2 and proliferation 
rate it is possible to distinguish between luminal A (HER2-, low grade) and luminal B (HER2+, 
high grade). Lumina A is the most commonly occurring with a frequency of 30% of all diagnosis, 
is characterized by the absence of the hormone receptors (HER2-), low pathological grade and 
proliferation rate consequently showing a good prognosis.  
On the contrary, the less frequent type Lumina B showed some overexpression of HER and tend 
to be higher histological grade than Lumina A, therefore belong to the higher proliferative grade. 
Although both luminal subtypes are associated with a good prognosis and long-term survival 
(approximately 80-85% 5-years survival), the luminal B is associated with a significantly worse 
prognosis compared to the other subtype[16].  
The HER2-enriched subtype is characterized by the overexpression of the human epidermal 
growth factor receptor, HER2. This subtype is usually ER‐/PR‐ /HER2+ and Accounts 
approximately for 17% of all breast cancers. It is generally associated with poor clinical outcomes 





The “basal-like” subtype, one of the most clinically aggressive subtype, is more commonly 
negative for all 3 markers ER, PgR and HER2 hence the “triple-negative” phenotypic classification 
[17]. 
 
1.3  CONVENTIONAL TREATMENT IN BREAST CANCER  
 
Breast cancer treatment include Surgery, radiation, chemotherapy and targeting therapy[18]. What  
guide the treatment choice are numerous factors such as stage of cancer, molecular profile, 
involvement in lymph nodes and presence of metastases [19]. 
Early breast cancer, defined when the malignant mass is contained in the breast or if anything has 
spread to the axillary lymph nodes, is considered curable [20]. Indeed, a combination of local 
treatment (surgery and radiation) and systemic treatment (chemotherapy and targeting therapy) 
has made it possible to increase chances for cure in ~ 70-80% of patients [18, 21].  
Usually, women with early stage breast cancer without metastasis undergo surgery, if the tumor is 
deemed operable. Although Surgery (resection) of the primary tumor is the cornerstone of curative 
breast cancer treatment, in most case a systemic therapy is required before (neoadjuvant) or after 
(adjuvant) surgery for decreasing the cancer mortality [22]. The treatment before resection aim to 
reduce the burden size, in this way, it is possible to decrease the invasiveness of the chirurgical 
practice and perform a breast- conserving surgery [23]. Indeed, it has been reported that in young 
women < 40 years of age breast conserving surgery plus whole radiation therapy renders 
equivalent overall survival compared with Mastectomy [24].  
The evaluation of the best systemic therapy after surgery depends on specific biomarkers such as 





HER2 treatment) or Ki67 expression (a value higher than 30% is correlated with high grade of 
proliferation and is typical of Lumina B tumor) [25].   
 In the case of Lumina A early breast cancer (ER+/PR+ low proliferation) adjuvant endocrine 
therapy is standard for at least 5 years after surgery. Typically, Tamoxifen is used, as an ovarian 
suppressor binding the estrogen receptor alone or associated with GnRH (Gonadotropin releasing 
hormone) which inhibit estradiol production. In post-menopausal women Tamoxifen is 
administered with aromatase inhibitor that helps to reduce the rate of recurrence. Several trials 
demonstrated that in high-risk patients the association improves DFS and overall survival 
compared with Tamoxifen alone [26-28]. 
In luminal HER2-negative early breast cancer, the chemotherapy is recommended beyond the 
endocrine therapy for the individual with high risk of recurrence. In this case, the Standard 
chemotherapy regimens include anthracycline and taxane given preferentially in sequence with 
attention to avoid excessive toxicity [29, 30]. Indeed, in patients with high clinical risk an 
anthracycline–taxane regimen seems to be superior compared with the cyclophosphamide- taxane 
treatment. For this kind of cytotoxic treatment, it has been demonstrated that Dose-dense 
administration of chemotherapy (in which the rate of delivery, rather than the overall dose, is 
increased) significantly improves 10-year breast cancer- related mortality independent of ER status 
and tumour burden without any detectable adverse effects on non- breast-cancer- related mortality. 
Adding drugs, such as capecitabine, gemcitabine or bevacizumab, to an anthracycline–taxane 
chemotherapy does not improve outcomes in early breast cancer [29].  
In HER2-positive early breast cancer (that is, luminal like and non- luminal-like HER2-positive 
early breast cancer), neoadjuvant chemotherapy together with anti- HER2 therapy has become the 





pertuzumab together with chemotherapy improves rates of pCR and therefore considered standard. 
Based on data from the adjuvant setting, chemotherapy may consist of either an anthracycline–
taxane sequence or a combination of docetaxel and carboplatin together with anti- HER2 therapy 
(for 1 year) [31-33]. 
In TNBC, chemotherapy is standard and typically contains an anthracycline and a taxane, although 
docetaxel and cyclophosphamide are equally effective, in TNBC with limited disease burden and 
could be used if anthracyclines need to be avoided. Finally, bone modifying agents such as 
bisphosphonates or the RANK- L antibody denosumab not only improve bone mineral density and 
decrease treatment related bone loss but may also improve patient outcomes. However, the data 
on denosumab in early breast cancer are controversial [31, 34, 35].  
 
1.4  BRAIN CANCER  
 
Brain and other central nervous system tumor collectively represent the cancer occurring in the 
brain and they count more than hundred intrinsic subtype according to the WHO. Firstly, it is 
possible to distinguish into primary or secondary tumor (metastatic). About 90% of cases are 
associated to primary tumor and are classified based on the similarity to a neural or glial precursor. 
Among the primary manifestation, the 30% are malignant and the most common types are: 
meningioma (37%), gliomas (25%), pituitary tumors (16%) and nerve sheath tumors (8%) as 





Figure 1.2: Primary brain tumor subtype [36]. 
 
Bailey and Cushing for the first time in 1920 classified the tumor of the glioma group referring to 
“Histological similarity principles” after observations that reveled a direct connection (or 
similarity) between the different type of glial tumor and a specific CNS cell of origin or its 
developmental precursor. According to this model, there is a correlation between the morphology 
of glial tumor and the differentiated stage of glia. For this classification reported in Figure 1.3 
Astrocytoma, for example, is the primary brain tumor composed by cells similar to Astrocytes or 
oligodedrogliomas is the subtype composed by cells similar to oligodendrocyte. Moreover, in high 
malignant setting, the tumor cells are similar to less differentiated precursor cells, whereas in less 
malignant setting they are more similar to neural tissue counterparts. The biological aggressiveness 





differentiation- and the presence of important features such as: mitotic activity, necrosis and 
vascular proliferation[37].   
 
Figure 1.3: The probable origins of glioma variants and medulloblastoma in the neuroglia lineage 
tree. Although the precise cells of origin for these cancers remain largely unknown, a selection of 
likely candidates For each (dashed arrows) is indicated.[38] 
1.4.1 Classification of brain cancer subtypes  
 
The WHO classification for brain cancer introduced in 2016 the genetic component and important 
molecular markers to define new entities within the histological classification. This integration 
made the classification more objective and helped the diagnosis and definition of treatment[39].   
However, the histology plays an important role for determining the grade of aggressiveness 





possible to distinguish into three big groups: i) malignances arising from glial cells; ii) arising from 
non-glial cells (neural cells); iii) metastatic tumor [40, 41].   
Medulloblastoma 
Medulloblastoma is a malignant tumor with higher incidence in children than adults that show a 
tendency to metastasize corresponding to WHO malignancy grade IV. Medulloblastoma occur in 
the posterior fossa. They consist of densely packed tumor cells with round or oval shaped 
hyperchromatic nuclei with scanty cytoplasm, high mitotic and apoptotic rates. The clinical 
outcome of patients with medulloblastoma varies according to age, postoperative tumor residuum, 
and metastatic (M) stage and, based on this, they are stratified into ‘‘standard’’ and ‘‘high’’ risk 
categories. A combination of chemotherapy and irradiation has allowed a long-term survival in the 
85% of the children older than 3 years of age and in 70% of high-risk patients.  
Metastatic brain cancer  
Brain metastasis usually arise from circulating tumor cells of a primary tumor including lung 
cancer (40%), breast cancer (17%), and melanoma (11%). Despite the significant advantages using 
microsurgery and radiosurgery the overall survival is still function of the primary cancer.  
Gliomas  
Gliomas are most common intracranial cancer in adults accounting for 80% of all malignant brain 
tumor. Gliomas does not have a specific area of origin in the CNS but surely arise from glial or 
precursor cells and are classified by WHO between grade I-IV based on malignant behavior. 
According to this classification, it is possible distinguish astrocyte, oligodendrocyte or both 
depending on the cells phenotype (grade I-IV). The incidence rate of pathology is confused by the 





incidence rate from different sources. The survival rate, significantly change for all histological 
subtype. The Pylicytic Astrocytoma has the highest 5 years relative survival and glioblastoma the 
poorest overall survival with only 0.05-4.7% of patients surviving 5 years after prognosis. Overall, 
the gliomas with oligodendroglial component have increased survival as opposed to those with 
astrocytic component. The age is considered as a significant parameter for survival expectation 
after prognosis mostly for glioblastoma.  
Glioblastoma grade IV, together with astrocytic tumor (grade II-III) and oligodendroglioma (grade 
III) are considered the most aggressive. 
1.4.2 Brain cancer treatment  
 
Brain cancer is one of the most aggressive tumor considering the high invasiveness, fast 
progression and inaccessibility for the majority of chemotherapeutic agents leading to poor 
prognosis and high rate of relapse. Currently, the standard procedures to treat patients with primary 
brain cancer includes surgery resection followed by radiotherapy and chemotherapeutic treatment 
with Temozolomide (TMZ). However, the current approved treatment do not provide long-term 
suppression of the tumor growth and they lack long-term efficacy causing in all patients a 
development of a recurrent disease. In addition, brain metastasis represent severe complication in 
the pathology.  Conventional treatment involves therapeutic antibodies, cetuximab and 
trastuzumab which are not able to cross the blood brain barrier (BBB). The BBB is deputed to 
control the homeostasis of CNS and brain functions by using a neurovascular unit (NUT) thinly 
regulated by endothelial cells (ECs), pericytes and astrocyte endfeets. However, this peculiar 
characteristic effectively limit the delivery of systemic therapies into the brain. The BBB included 





disruptions are present due to tumor progression. Indeed, during tumor development the 
uncontrolled cells proliferation induces the rapid formation of new blood vessels to provide 
nutrients and oxygen.  The effect it is commonly defined as Enhanced Permeability and Retention 
effect that always characterize the tumor endothelium. In spite of the higher permeability of the 
BTB, there is an insufficient accumulation of both small and large molecules and this remain as 
the rate-limiting factor for effective therapy. The neurovascular unit that compose the capillary 
bed of neuroparenchyma is composed of endothelial cells connected with thin junctions (TJs) 
surrounded by specialized basal lamina that are in communication with perycites and astrocytes 
endfeets. All together, they form a specialized system that control cellular and extracellular 
network, regulating the transport of toxic byproducts and essential molecules, avoiding the passive 
paracellular diffusion of molecules with a mass higher than 150 Da or slightly more if they are 
highly hydrophobic compounds. 
2   NANOMEDICINE FOR CANCER THERAPY  
 
2.1 DRUG DELIVERY SYSTEM  
 
Over the past years, the translation of Nanotechnology efforts for medical applications and 
especially for cancer investigation has allowed to appreciate their unique features for drug 
delivery, diagnosis and imaging intents [42]. Nanotechnology is defined as the science focused on 
the synthesis, characterization and application of tools and devices within the nanometer scale 
(around 100 nm or smaller). At the nanoscale, fundamental proprieties of a given material can be 
precisely controlled by nanotechnology without chemical modification such as optical  or magnetic 





therapeutic and imaging intent has the potential to revolutionize the idea of conventional medicine 
opening an offshoot of nanotechnology defined as Nanomedicine [43, 44].  
Nanomedicine usually involves numerous type of devices including nanoparticles, nanomachines, 
nanofibers or other nanoscale microconstructs. Materials that showed a particular behavior 
including Nano shells, iron oxide nanocrystals or quantum dots has been used for diagnostic 
purposes. For example, gold nano-shells are opticaly tunable nanoparticles composed of a 
dielectric core of silica covered by a thin gold shell [45]. Indeed, changing the shell thickness and 
core size they are able to absorb and/or scatter light in a broad range of wavelength including 
Infrared zone that provide the maximal penetration of light through tissue. Whereas, Iron oxide 
nanocrystals given the superparamagnetic proprieties are used as contrast agent in magnetic 
resonance imaging showing high diagnostic accuracy in atherosclerosis, arthritis and cancer 
detection[46]. Although the potent improvement in imaging and diagnosis, the clinical application 
is often limited by toxicity, instability and lack of specificity. Therefore, in recent years, 
biocompatible polymers such as poly (ethylene glycol) (PEG) has been largely used to preserve 
the metal degradation and allow their blood circulation [47].   
The concept of nanomedicine aim to improve the therapeutic index of anticancer drug by 
modifying their pharmacokinetics and tissue distribution by improving the delivery to the site of 
action. Current treatment for cancer include the use of chemotherapeutic drugs characterized by 
high cytotoxicity and no preferential accumulation at target site causing severe toxicity towards 
patients. Therefore, to provide a more efficient and safe solution it is desirable to develop smart 
Nano therapy that is able to recognize the tumor environment and selectively release the drugs. In 
the recent years these Nano-sized delivery systems, are being used for targeted therapy (active or 





achieving a significant improvement of drug therapeutic index with reduced adverse effects [48]. 
Moreover, Nano carrier-based strategies encapsulate the molecules within a complex of natural or 
synthetic polymer matrix allowing to control the pharmacokinetic profile of the cargo to sustain 
their release for a long time and only in a specific environment [49, 50]. 
For this purpose, the understanding of the tumor biology has opened the way to design rationally 
a platform suitable for the preferential accumulation within tumor tissues. The first findings on 
tumor biology reveled important features such as leaky blood vessel and poor lymphatic drainage. 
Therefore, several nano-sized delivery systems have been designed according to the peculiar 
anatomical organization of tumors neo-vasculature [49, 51]. The vessels surrounding tumor mass 
are leaky and present bigger fenestrations, and consequently they are more permeable than the 
normal ones[52]. The increased permeability of tumor vasculature is also due to the inflammation  
that is present in tumor microenvironment [53]. This scenario is even more complicated by the less 
efficient recovery of molecules due to the inadequate development of the lymphatic system in the 
tumor area. The particular anatomical organization, gives rise to the Enhanced Permeation and 
Retention (EPR) effect through which drug delivery systems in the nanometer scale could target 
passively tumors considering also that the molecular cut-off for the extravasation in tumor tissues 
range from 50 to 400 nm [54, 55]. 
Conventional drug delivery platforms mainly developed for tumor targeting up to now present a 
spherical shape and a size smaller than 200 nm suitable for extravasation upon systemic 
injection[56]. Liposome containing Doxorubicin (Doxil) was the first nanomedicine approved for 
clinical treatment, as reported in the time line in Figure 2.1  and nanotechnology-based 
therapeutics along with other polymeric delivery system still represents a large portion of clinically 






Figure 2.1: Historical timeline of major developments in the field of cancer nanomedicine [47] 
 
Nanoparticles can be made out of different materials and they have various physiochemical 
proprieties such as size, geometry, surface features, stiffness, among others, and all of them play 
an important role in regulating the processes involved in the actual delivery of the payload at the 
tumor tissue [58-60]. The family of Nano carriers includes polymer conjugate, polymeric 
nanoparticles, lipid-based carriers such as liposome and micelles, dendrimers, carbon nanotube 
and gold nanoparticles. They have been used for a variety of application such as drug delivery, 
imaging, phototermal ablation of tumors, radiation sensitizers and detection of apoptosis. Notably, 
the use of biodegradable and biocompatible materials has allowed mitigating the limitations 
ascribed to the use of excipients to solubilize hydrophobic drug in water as in the case of Paclitaxel 
[61].  Indeed, the use Albumin-bound paclitaxel has been the second class of Nano formulation 
that reached the market (nab-paclitaxel; abraxane). Albumin-paclitaxel complex have showed a 
better performance in terms of response rate and time to progression evaluated in patients with 





excipient[62]. A panel summarizing the main formulations approved by FDA or already in clinical 
















2.2  NANO CARRIER ASPECTS FOR TUMOR TARGETING 
 
Since the 1986, the definition of the enhanced permeability of the tumor vessel has supported the 
statement that nanoparticles with sufficient size cut-off and long circulation times are able to 
accumulate passively within malignant tissue thanks to a physiological condition of the malignant 
neo-vascularization. However, a recent meta-analysis conducted on a large body of work published 
over the past years show that in many cases, less than 1% of the administered dose reach the 
malignant tissue [60]. To note, the use of nanoparticles to deliver chemotherapeutics increase the 
stability of the drug, improve the Pharmacokinetics and therefore the residence time of the drug 
after administration [64]. That justifies the decreased toxicity in clinical trial and the 
commercialization of few formulations as reported above (Table 2).  However, the design of Nano-
carrier for tumor targeting require the evaluation of the physiological aspects that may limit their 
bioavailability after systemic administration [60]. The size, shape and mechanical stiffness of 
nanoparticles are critical for vascular transport, Mononuclear phagocyte system (MPS) 
sequestration, blood longevity and tumor deposition [65-67].  
While in the bloodstream, Nanoparticles encounter numerous biological barriers that limit their in 
vivo performance and favor their clearance in a short time. The principals circulating factors such 
as body elimination, blood flow and recognition by phagocytic cells can reduce Nanoparticles 
stability and hence lead to accumulation in tumor environment after administration. The specific 
effect of these biological factors are dependent on the physiochemical properties of the particles 
such as size, shape and surface properties  leading to define general principles aimed to manipulate 





a small diameter around 10 nm have demonstrated rapid elimination by kidney, whereas particles 
larger than 200 nm provoked the activation of the complement system if not modified.[69]  
In this regard, hydrophilic polymer like Polyethylene- glycol (PEG) has helped to improve the 
circulation time shielding the particles surface from enzyme and antibody that may induce 
degradation and clearance conferring them stealth properties. In contrast, studies demonstrated 
that exposure to PEG caused the production of anti- PEG antibodies that can induce the rapid 
clearance of PEGylated NPs [70]. Another method tested included the use of platelet membrane 
cloaking which deceive the complement system but not the uptake from other cell population[71]. 
However, the plate-based cell interaction help to target the injury site owing to the ligands present 
on the surface such as mediators adhesion, Von Will brand factors and collagen pushing the 
wrapped nanoparticles around activated platelets [72]. In addition, proper modifications to hide 
the circulating NP helps from the sequestration by mononuclear phagocytic cells and RES which 
are responsible in overseeing the blood circulation from pathologists and undesired agents hence 
for the clearance of NP. They includes macrophages, monocytes and dendritic cells that quickly 
phagocytize particles and accumulate in spleen and liver. The sequestration by immune cells 
happen more rapidly for cationic and stiffer particles, whereas neutral or weakly negative particles 
have longer circulation half- life. Besides the clearance, the interaction between NP and MPS may 
cause toxicity due to the initiation of immune response, which involves the activation of tumor 
necrosis factors, interleukin and interferon that causes inflammation and tissue damage. Despite 
the success of FDA-approved nanodrugs in reducing the toxicity associated with the active 
pharmaceutical ingredients (API), the clinical application of them has thus far showed a limited 
improvement in overall survival of patients. Several hypothesis have been suggested by scientists 





evidences that reveled a complicated fate for nanoparticles injected systemically. For example, it 
is commonly know that the major obstacles for an increased efficacy of anticancer treatments relies 
on a feeble tumor penetration. An approach to boost tumor permeability is the application of tumor 
penetrating peptide on the surface of nano-drugs. The peptide is able to bind to a surface receptor 
specific for the blood vessels, tumor cells and stroma. Then the proteolytic cleavage shift the 
affinity for neutrophilin-1 receptor causing activation of the endocytic/exocytose trans-tissue 
transport pathway and therefor to an increased tumor penetration of small nanoparticles [73]. 
However, this approach has showed low effects due to low picomolar concentration of the target. 
Therefore, other efforts were presented focusing on the tumor microenvironment through radio 
frequency or high intensity focused ultrasound (HIFU) that effectively caused a remodeling of the 
tumor microenvironment and therefor enhanced nondrug accumulation leading to improved 
therapeutic efficacy [74]. Finally, a significant improvement in delivering payload in tumor 
targeting was achieved using the natural tropism of cell-delivered vehicles to tumors such as ghost 
of stem cells  (naoghost) associated with tumor cells thought cellular uptake (endocytosis pathway) 
and via cellular binding ( absorption, lipid exchange, fusion). 
 
2.3  THE EPR EFFECT IN NANO MEDICINE DEVELOPMENT  
 
 The EPR effect clearly explain the enhanced accumulation and prolonged retention of NP in solid 
tumor compared with normal tissue. The majority of approved anticancer Nano medicines have 
been designed to exploit the concept of the EPR effect with a small subset of Nano medicine 
seeking to alter nanomedicine behavior further with ligand mediated targeting. In general, the use 
of EPR based therapeutics aimed to improve efficacy and tolerability by enhancing the 





concentration (Cmax) and increasing the area under the curve in plasma and tumor, the Nano 
delivery system provides a prolonged exposure to therapeutic and enhanced drug concentration at 
the target. Notably by reaching the right site and the right exposure, several Nano medicine have 
conferred a significantly enhanced therapeutic index to an existing therapy as for cerulean, a 
Nanoparticle formulation marketed by AstraZeneca as AZD2811.  
However, new nanomedicine platforms suffer from poor clinical translation as was for the early 
antibodies therapeutics causing a slow market progression and the greater failure could be ascribed 
to our poor understanding of the disease heterogeneity in the patient population [75].  
As highlighted above, traditionally, the research in nanomedicine field have been focused to adapt 
the physico-chemical parameters of a delivery system therefore loading, chemistry, size, charge 
and surface modification to control its in vivo behavior. Nevertheless, the heterogeneity of tumor 
patient has been overlooked and the correlation with nanomedicine behavior that causes their 
major limitation for optimal performance in clinic. Indeed, The practical evaluation of EPR effect 
in human tumor are relatively costly and time consuming , moreover the currently available 
methodologies still faces challenge in sufficient resolution. Although several studies has been 
performed using sophisticated techniques, they require expensive equipment not accessible for 
many laboratories. For example, a gamma-scintigraphy/SPECT imaging was used in a study 
involving few patients to follow indium/ technetium labeled liposome upon systemic injection[76]. 
Data revealed that the tumor accumulation varied between tumor type ranging from 3-5% of the 
injected dose in the case of breast cancer to the 33-16% in head and neck cancer. Thus disclosing 
that the access and/or accumulation of the nanomedicine may be disease dependent and differ from 
one tumor to the other [55-56]. Furthermore, a confirmation of the inter-tumor variability came 





showed substantial heterogeneity in the level of liposome uptake, as measured by CT/PET 
scanning [60]. 
Therefore, if tumor EPR is the driving principle in the design characteristics of a nanomedicine, 
then it is essential to treat tumors which present an EPR effect, as obviously variability in the level 
of EPR effect, or even a complete lack of an EPR effect, would significantly impact the clinical 
outcome.  
2.4 TARGETING THE VASCULATURE USING DISCOIDAL NANOCONSTRUCTS  
 
The nanoparticles relying mostly on EPR effect to reach target site represent the main category 
described over the last decades in literature. However, the presence of fenestrations is not the only 
peculiarity of tumor vasculature. For instance, tumor mass present also a tortuous vascular 
network, low mean blood velocity, impaired lymphatic system and high interstitial fluid pressure.  
This environment prevents the penetration of nanosized drugs deep within the tumor and, 
therefore, contributes to tumor progression, metastasis and drug resistance. On the contrary, all 
these peculiarities can be used for the preferential accumulation of particles without relying on 
EPR effect. Interestingly, red blood cells (RBc) represent the majority of corpuscles in the 
circulation and accumulate within the vessel core creating a “cell free layer” next to the wall. This 
behavior is responsible of the migration, wall adhesion and extravasation of leukocytes and 
platelets and it is relevant in the case of inflammation [77].   
Therefore, a second class of platform developed during these years represented by discoidal 
nanoconstruct targeting mostly the malignant vasculature. This category was designed to 





penetrating the endothelial fenestration. Their size and shape determine its possibility  to be pushed 
laterally in the “cell-free” layer and they consequently accost closely to the vessel walls and 


















3 CHAPTER 1: VASCULAR-CONFINED MULTI-PASSAGE 
DISCOIDAL NANOCONSTRUCTS FOR THE LOW-DOSE 
DOCETAXEL INHIBITION OF TRIPLE-NEGATIVE BREAST 
CANCER GROWTH 
 
3.1 ABSTRACT  
 
Insufficient tumor accumulation and severe off-target effects limit Taxol efficacy in Triple 
Negative Breast Cancer (TNBC). Nanomedicines offer the unique opportunity to enhance the 
potency of taxanes against such aggressive molecular subtype of breast cancer which are 
unresponsive to typical endocrine therapies. Here, 1,000x400 nm Discoidal Polymeric 
Nanoconstructs (DPNs) were engineered to encapsulate docetaxel (DTXL) and the near infra-red 
compound lipid-Cy5. DPNs were obtained by filling cylindrical wells in a poly(vinyl alcohol) 
template with a polymer mixture comprising poly(lactic-co-glycolic acid) (PLGA), poly(ethylene 
glycol)-diacrylate (PEG-DA), and the therapeutic and imaging agents. A ‘multi-passage’ loading 
strategy was proposed to improve DTXL encapsulation and release while ensuring lipid-Cy5 
stability. Confocal microscopy confirmed that DTXL-DPNs were not taken up by MDA-MB-231 
cells but would rather sit next to the plasma membrane and slowly release DTXL thereof. In 
orthotopic murine models, Cy5-DPNs efficiently accumulated in TNBC masses with a tumor-to-
abdomen ratio of 1.3. With only 2 mg/kg of DTXL, intravenously administered every other day 
for 13 times, DTXL-DPNs induced tumor regression returning an 80% survival rate at 120 days 
as compared to 30% with free DTXL. Collectively, this data demonstrates that effective, low-dose 
tumor treatments can be achieved with vascular confined nanoconstructs by-passing the enhanced 







Breast cancer is the most common malignancy in females and the second leading cause of cancer 
related deaths [5]. About 20% of breast cancers are negative for both hormones – estrogen and 
progesterone, and HER2 receptors. This phenotype characterizes the breast malignancy with the 
most dismal prognosis, known as the triple negative breast cancer (TNBC) [78], showing a faster 
growth rate and higher likelihood of relapse at secondary sites as compared to hormone positive 
breast cancers [17]. As hormones and HER2 are not fueling cancer growth, TNBC are 
unresponsive to typical endocrine therapies. Consequently, the poor outcome of TNBC patients is 
also attributed to the limited availability of effective therapeutic strategies [79, 80]. In addition, 
the significant tumor heterogeneity in TNBC has hindered the success of targeted medicines, such 
as tamoxifen and Herceptin [81]. Therefore, TNBC treatment still remains a challenge and, to date, 
the combination of surgery, radiation therapy and chemotherapy is the sole option for primary 
mases [82-84], whereas systemic chemotherapy is used for attacking metastatic niches [85]. 
Among the plethora of clinically approved chemotherapeutic molecules, docetaxel (DTXL) is one 
of the most potent but is also responsible for severe adverse reactions due to its non-specific 
accumulation in healthy tissues [86] and the need of toxic solubilizing agents  [87, 88]. For this, 
the administered doses are often limited, thus significantly impairing the DTXL cytotoxic activity 
within the tumor tissue [89, 90]. 
In this scenario, Nanomedicine could play a fundamental role to increase the therapeutic efficacy 
of small anti-cancer molecules optimizing their bioavailability, tissue deposition, and cellular 
uptake while limiting off-site targeting [62, 75, 91, 92]. Traditionally, spherical nanoparticles with 
a sufficiently small size (< 200 nm) have been designed to cross the hyperpermeable tumor 





[93, 94]. By passing through the ‘fenestrated’ endothelium, spherical nanoparticles can reach the 
tumor parenchyma and progressively accumulate therein, given the lack of a functional lymphatic 
drainage. A variety of EPR-dependent delivery systems for taxanes have been designed in the 
context of TNBC therapy, including macromolecular conjugations [95], liposomes [96], polymeric 
nanoparticles [97-99], micelles [100] and prodrugs [101]. Some of these platforms are already 
approved for clinical use or under clinical investigation [92, 102]. For instance, the albumin-bound 
(nab)-paclitaxel (Abraxane) was approved by FDA in 2005 as a second-line treatment of metastatic 
breast cancer [62]. Interestingly, the clinical use of Abraxane is associated with lower systemic 
toxicity and only a modest improvement in the therapeutic index [62, 103]. Other taxane-loaded 
polymeric micelles and nanoparticles, at different stages of clinical development, presented similar 
outcomes for both primary and metastatic TNBC [100, 104-106].  Recently, Rafael Contreras-
Cáceres et al. [107] developed a pH-sensitive nano-carrier encapsulating Paclitaxel within the 
hollow structure of oxidized poly(4-vinyl pyridine) and demonstrated an improved antitumor 
activity on A-549 and MCF-7 multicellular tumor spheroids (MTS), as compared to the free drug. 
In other nanoparticle formulations, a targeting moiety was included on the nanoparticle surface to 
enhance tumor accumulation and deep penetration into the malignant mass [91, 108-110]. The cell 
receptor CD44 has been extensively investigated as a targeting molecule in TNBC. For instance, 
Huang et al. demonstrated that CD44-targeted docetaxel-loaded nanoparticles have enhanced 
antitumor activity over the untargeted nanoparticles [108]. De-Sheng Liang and colleagues 
implemented a dual targeting approach including on the same nanoparticle moieties to recognize 
CD44 molecules, expressed on the cancer cells and neuropilin receptors, exposed on the tumor 
neovasculature. This approach succeeded in suppressing tumor cell invasiveness and metastatic 





shown to highly accumulate in MDA-MB-231 xenografts and in the metastatic lymph nodes of 
nude rats by SPECT/CT imaging [110].  
For all the above listed nanoparticles and many more proposed in the open literature, tumor 
accumulation via the EPR effect has been always been sufficient to modulate disease progression 
or even induce regression. However, these encouraging preclinical results often have not been 
translated in clinical settings for a number of reasons. First, the permeability of the tumor 
neovasculature to nanoparticles is highly heterogeneous, both at the intra- and inter-patient levels 
[60, 94, 111, 112]. Second, targeting may improve nanoparticle retention in tumors, but could also 
favor sequestration by cells of the immune system [113]. Furthermore, bio-conjugation may not 
be intrinsically that specific because targeting receptors could also be expressed on healthy cells 
or the orientation of the moieties over the particle surface could be sub-optimal thus impairing the 
proper biological recognition. Along this line, a recent meta-analysis revealed that active targeting 
agents yield only modest improvements in intratumor nanoparticle accumulation [60]. In this 
scenario, designing particles to target and accumulate within the tumor vasculature without relying 
on the EPR effect could be a valuable, complementary strategy [114-117]. The tumor vasculature 
is tortuous and characterized by lower flow rates as compared to healthy vascular beds. This 
specific hemodynamic conditions and vascular architecture would favor the deposition of non-
spherical micrometric particles over more conventional spherical nanoparticles [117-120]. These 
micrometric particles would mimic the behavior of circulating platelets, thus confirming the 
importance of bioinspiration and biomimicry in the development of novel drug delivery systems 
[121]. Indeed, the authors have previously demonstrated that discoidal particles can lodge within 





In this work, we presented a novel class of Discoidal Polymeric Nanoconstructs (DPNs) to boost 
drug loading and release at the targeted site without relying on the EPR effect. Specifically, 
1,000400 nm DPNs were directly loaded with the potent anti-cancer drug docetaxel (DTXL) and 
realized using a ‘multi-passage’ loading strategy. A comparison between the ‘multi-passage’ and 
‘single-passage’ DPNs was first presented in terms of morphological, physico-chemical, and in 
vitro pharmacological characterizations. Then, the therapeutic efficacy and imaging efficiency of 
DTXL and Cy5-loaded DPN was tested preclinically in mice bearing an orthotopic model of triple 
negative breast cancer. 
 
3.3 EXPERIMENTAL 
3.3.1 Chemicals.  
 
Polydimethylsiloxane (PDMS) (Sylgard 184) were purchased from Dow Coming Corp (Midland, 
USA). Poly(vinylalcohol) (PVA, Mw 31,000 - 50,000), Poly(DL-lactide-coglycolide) acid 
(PLGA, lactide:glycolide 50:50, Mw 38,000-54,000), Poly(ethylene glycol) diacrylate (Mn 750) 
(PEG diacrylate), 2-Hydroxy-40-(2-hydroxyethoxy)-2-methylpropiophenone (Photo-initiator) 
were purchased from Sigma-Aldrich (Missouri, USA), Rhodamin-B (lipid-RhodB) was purchased 
from Avanti Polar Lipids (Alabama, USA). Docetaxel was purchased from Alfa Easer 
(Massachusetts, USA)  
3.3.2  Methods  






 Discoidal polymeric nanoconstructs (DPNs) were synthetized using a top-down fabrication 
strategy described in details in previous works by the authors [122, 123]. Briefly, the process 
started with the fabrication of the silicon master template via Laser Writer Lithography. This 
technique was used to imprint on a silicon wafer a specific pattern of wells with the geometry of 
the final DPN. Then, a solution composed by polydimethylsiloxane (PDMS – Sylgard 184) (10-
parts base elastomer and 1-part curing agent) was cast over the Silicon wafer to reproduce a 
negative replica of it. Finally, a sacrificial template was realized by pouring a 5% w/v poly(vinyl 
alcohol) (PVA) solution on the PDMS template and letting the solution dry at 60° C for about 3 h. 
Once polymerized, the hydrophilic PVA template reproduced the same cylindrical holes of the 
original silicon master. DPN were synthetized using a mixture of poly(lactic acid-co-glycolic acid) 
(PLGA) and poly(ethylene glycol) diacrylate (PEG DA) polymers. 50 mg of PLGA was dissolved 
in 1 mL of Acetonitrile and mixed with 6 mg of PEG-DA and 10 mg of docetaxel (DTXL). Then, 
0.6 mg of a photo-initiator (2-Hydroxy-4’-(2- hydroxyethoxy)-2-methylpropiophenone) was 
added into the polymeric solution to allow the crosslinking of PEG diacrylate chains after exposure 
to UV-light (366 nm). A fixed volume of polymeric mixture, including docetaxel (5 µL), was then 
spread with a blade over the PVA template to accurately fill each well. This step was performed 
one time for the ‘single-passage’ DPN and about 4-5 times till complete solvent evaporation for 
the ‘multi-passage’ DPN. Finally, the DPNs were released from the hydrophilic PVA templates 
upon dissolution in deionized water for 3h under gentle stirring, were collected through 
centrifugation (3,900 rpm for 20 min) and purified from residual debris and scum layer through 2 
μm filtration (Sterlitech).  






The DPN geometry and synthesis yielding was assessed through Multisizer 4E Coulter Particle 
Counter (Beckman Coulter, USA), that calculated particle concentration in a defined volume of 
20 mL of isotone solution. The hydrodynamic diameter and surface electrostatic charge (ζ – 
potential) of DPN was measured using a Zetasizer Nano (Malvern, UK). The characteristic 
discoidal shape of DPN was confirmed using Electron Microscopy.  DPN morphology was 
observed using a Jem-1011 Transmission Electron Microscope (Jeol, Japan) coated with sputtered 
carbon and Scanning Electron Microscopy (Helios Nanolab 650) after 10 nm aureum coating. 
Fluorescent DPN were synthesized by adding 30 µg of Rhodamin-B (DSPE-RhB) to the polymeric 
mix made of PLGA and PEGDA and were observed using an A1 confocal fluorescent microscope 
(Nikon).  
 Loading and Release studies.  
 
The ‘direct loading’ method was used to uniformly disperse imaging and therapeutic agents within 
the DPN matrix [123, 124]. Specifically, a 5 µl homogenous drug/polymer solution was uniformly 
spread using a blade over the surface of a 33 cm PVA template, containing about 108 wells. This 
step was performed only once for the ‘single-passage’ DPN and several times till complete solvent 
evaporation for the ‘multi-passage’ DPN. This loading strategy was different from the ‘absorbance 
loading’ previously described by the authors [123]. The amount of drug loaded within DPN was 
calculated using a HPLC and by reading the characteristic docetaxel UV absorbance at 230 nm 
(Agilent 1260 Infinity, Germany). Samples for HPLC analysis were prepared by spinning down 
DPN at 12,700 RPM for 20 min, drying the pellet overnight and dissolving the particles upon 
incubation with acetonitrile (ACN). The encapsulation efficiency was calculated considering the 





synthesis process and the initial drug input. Release studies were performed in a volume of 4L of 
buffer at controlled pH 7.4 and 37° C to reproduce typical physiological conditions. At each time 
point, 200 µL of DPN solution was poured into Slide-A-Lyzer MINI dialysis cups with a molecular 
cut off of 10 kDa (Thermo Scientific) and dialyzed. At each time point, DPN were collected and 
dissolved in ACN to read the amount of DTXL still entrapped in the matrix overtime.  
 In vitro cell viability tests. 
 
 For cytotoxicity tests in vitro, the human Triple Negative Breast Cancer cell line MDA-MB231 
was obtained from the American Type Culture Collection (ATCC). Cells were cultured in Eagle's 
minimal essential medium (EMEM) (ATCC, USA) completed with 10% FBS (Gibco, Thermo 
Fisher Scientific, USA), 1% penicillin/streptomycin (Sigma-Aldrich, USA), under a humid 
atmosphere (37°C, 5% CO2, 95% air). Cell viability was determined by MTT assay, which detects 
the reduction of MTT (3-(4,5-dimethylthiazolyl)-2,5- diphenyltetrazolium bromide) (Sigma-
Aldrich, USA) by mitochondrial dehydrogenase to blue formazan product. This reflects the normal 
function of mitochondria and, hence, cell viability. Briefly, different number of cells were seeded 
in 96-well plates for each time point, specifically 104 cells/well for the 24h, 7.5x103 for 48h, and 
5 x103 for 72h were seeded in 96-well plates and incubated at 37°C, 5% CO2, for 24 h. The day 
after, cells were treated with EMEM containing the selected doses of DTXL and DTXL- DPN (0.1 
– 1,000 nM).  After 24, 48 and 72 h, the treatment solution was removed and replaced by MTT 
solutions, according to the manufacturer’s instructions. The resulting formazan crystals were then 
dissolved in ethanol (200 μL/well) and the absorbance was read at 570 nm using a microplate 





collected when the absorbance ranged between 0.8 and 1.2. Cell viability was normalized to that 
of untreated cells. 
 Cell Uptake experiments.  
 
To assess DPN internalization, 4104 MDA-MB-231 were seeded into 8 well cover slides and 
treated with the DPN at a concentration of 10 DPN/cell.  After 2h, 4h, 8h and 24h incubation, cells 
were fixed using 4% paraformaldehyde and DPN uptake was studied via Z-stacks analysis 
performed on a Nikon confocal fluorescent microscope. For these studies, RhB-DPN were used. 
 Optical imaging of orthotopic breast cancer. 
 
 0.9 million of MDA-MB-231 luciferin positive cells were injected in the 3rd mammary fat pad of 
female CD1 immunodeficient nude mice to allow the development of orthotopic breast cancer. 
The growth of the tumor mass was followed by whole animal optical imaging (IVIS Spectrum 
system, Perkin-Elmer) until 4 weeks post cells inoculation. Once tumors reached an average 
radiance in the order of 108 [p/s/cm²/sr], mice were intravenously injected with Cy5-DPN.  
 Tumor model and therapeutic experiments. 
 
 All animal experiments were performed according to the guidelines established by the European 
Communities Council Directive (Directive 2010/63/EU of 22 September 2010) and approved by 
the National Council on Animal Care of the Italian Ministry of Health. All efforts were made to 
minimize animal suffering and use the lowest possible number of animals required to produce 
statistical relevant results, according to the “3Rs concept”. For the orthotopic breast tumor model, 





Animals were grouped in ventilated cages and able to freely access food and water. They were 
maintained under controlled conditions: temperature (21 ± 2 °C), humidity (50 ± 10%) and light 
(12 and 12 h of light and dark, respectively). Before injection of cells, animals were anaesthetized 
with a mixture of ketamine (10%) and xylazine (5%), which was administered via a single 
intraperitoneal injection. For the injection, trypsinized 0.9107 MDA-MB-231 luciferase positive 
cells were resuspended in cold matrigel solution. A total of 100 l of matrigel was subcutaneously 
injected into the third mammary fat gland. Animals were carefully monitored until recovered from 
anesthesia. Tumor growth was followed by IVIS Spectrum system every 2 day, upon 
intraperitoneal injection of D-luciferin, Potassium salt (GoldBio) at a dose of 150 mg/Kg and by 
caliper measurement. Tumor growth was calculated by tumor volume (V) with the formula V = W 
2 × L /2 (W = width; L = length). When tumors reached an overall volume of about 0.15 cm3, mice 
were randomized into three groups (six mice per group). The groups were dosed for 30 day by 
retro-orbital injection every 2 day with saline, Free-DTXL and DTXL-DPNs. Each injected dose 
contained 40 μg of docetaxel into DPN or as commercial clinical formulation. The therapeutic 
efficacy of the different treatments was evaluated by whole animal optical imaging (IVIS Spectrum 
system) and caliper measurement every two days. All mice were euthanized when they became 
moribund or tumor volume passed a volume of 1 cm3. Survival was monitored and plotted using 
the Kaplan-Meier method.  
 Statistical Analysis.  
 
All data were processed using Excel 2010 software (Microsoft) and GraphPad PRISM. Results 
were expressed as mean + standard deviation. Statistical analyses on in-vivo experiments were 









3.4 RESULTS AND DISCUSSIONS 
3.4.1 ‘Multi-passage’ loaded Discoidal Polymeric Nanoconstructs.  
 
The particle fabrication comprises of a number of sequential steps (Figure 3.1 A) through which 
the 4S parameters of DPN – size, shape, surface properties and mechanical stiffness – were 
precisely tailored in order to optimize their in vitro and in vivo performance. Briefly, the initial 
manufacturing step involved the use of a direct laser writing system to realize a silicon master 
template with billions of wells per wafer presenting a well-defined geometry. In the present study, 
the wells in the silicon wafer were cylinders with a 1,000 nm diameter and a 400 nm depth 
(Figure 3.1 B). Then, a soft lithographic technique was used to generate multiple negative replicas 
of the original master template in polydimethylsiloxane (PDMS) (Figure 3.1 C). The wells in the 
master template were turned into cylindrical posts, comparable in diameter and height to the wells. 
Finally, the PDMS template was replicated into multiple polyvinyl alcohol (PVA), sacrificial 
templates presenting wells with the same geometry as in the master silicon template (Figure 3.1 
D). After drying the PVA template, its wells were accurately filled by uniformly spreading a 
polymeric paste. This comprised of an homogeneous mixture of the hydrophobic poly(D,L-lactide-
co-glycolide)-acid carboxylic terminated (PLGA-COOH) and hydrophilic poly(ethylene glycol) 





and PEG-DA mixture formed the actual polymeric matrix of DPN, which was characterized by 
hydrophobic and hydrophilic pockets entrapping the loaded agents. In the current configuration, 
the chemotherapeutic molecule docetaxel (DTXL) and the red fluorescent molecule RhB-DSPE 
or the near-infra red molecule Cy5-DSPE were dispersed within the polymer matrix. To release 
and collect the DPN loaded with DTXL and Cy5-DSPE, the PVA templates were dissolved in 
water for 3 hours at room temperature and under gentle stirring (Figure 3.1 A). Differently the 
previous authors’ practice [123], in this work, the spreading of the polymeric paste on the PVA 













Figure 3.1: DPNs morphological characterization. A. Schematic representation of the DPN 
fabrication and purification process (left). Structure and molecular constituents of DPNs (right). 
Scanning Electron Microscopy images of the templates. B. Silicon master template; C. PDMS 





This modification in the fabrication protocol, named ‘multi-passage’ loading, allowed the authors 
to increase the amounts of loaded agents per particle and thus, improve the DPN pharmacological 
and imaging properties as compared to the previous configuration (‘single-passage’ loading).  
The morphological properties of the ‘multi-passage’ loaded DPN were investigated using scanning 
electron microscopy (SEM) (Figure 3.2 A), transmission electron microscopy (TEM) (Figure 3.2 
B) and confocal fluorescent microscopy (Figure 3.2 C). As compared to the ‘single-passage’ 
method, the electron and optical density of the ‘multi-passage’ DPN were higher suggesting a 
larger mass of polymers and fluorescent imaging probes trapped within the matrix, as can be 
inferred by looking at Figure 3.2 B-C. The DPN morphological and physico-chemical properties 
were also characterized by using a Multisizer Particle Counter and a Zetasizer Nano (Figure 3.2 
D-F). The Multisizer Particle Counter spectrum for the ‘multi-passage’ DPN showed a sharp peak 
around 700 ± 150 nm that is slightly, but not significantly (p = 0.1), larger than for the ‘single-
passage’ DPN (670 ± 100  nm) (Figure 3.2 D – ‘single-passage’: purple; ‘multi-passage’: blue). 
This again would imply that the ‘multi-passage’ strategy allows for a more accurate filling of the 
PVA wells with the polymer and functional agents without changing DPN geometrical proprieties. 
The Dynamic Light Scattering (DLS) analysis (Figure3.2 E,F) showed a uniform and 
monodispersed size distribution for the ‘multi-passage’ DPN around 880 ± 200 nm and a negative 
surface charge  of – 32 ± 0.15 mV, ensuring the colloidal stability of the suspension. Even the 
DLS analysis confirmed a small difference in size between the ‘single-passage’ and ‘multi-
passage’ DPN design (p=0.5). (Figure 3.2 E,F – ‘single-passage’: purple; ‘multi-passage’: blue). 





properties of DPNs. Overall, the data of Figure 3.2 confirm that the DPN size, shape and surface 
properties are well preserved.  
 
 
Figure 3.2: DPNs morphological characterization. A. Scanning Electron Microscopy of DPNs. 
B. Transmission Electron Microscopy of a single DPNs. C. Confocal Fluorescent Microscopy of a 
DPN loaded with Rhodamine B – DSPE. D. Size distribution and number of DPNs measured via 
a Multisizer Coulter Counter system. E. DPN size distribution measured via Dynamic Light 
Scattering. F. Surface electrostatic -potential of DPNs (purple curve: ‘single-passage’ vs blue 
curve: ‘multi-passage’).  
3.4.2 Controlled drug release and in vitro cytotoxicity.  
 
So far, RhB-DSPE was consistently loaded into DPN to highlight the particle morphological 
features via fluorescent microscopy. Following the same strategy, any other imaging agent and 





chemotherapeutic drug docetaxel (DTXL) was dispersed directly within the polymer paste and 
loaded into DPN. The encapsulation efficiency (EE%) and release profile of DTXL over time are 
presented in Figure 3.3 A-B, as derived by high performance liquid chromatography (HPLC). A 
direct comparison between the ‘single-passage’ and ‘multi-passage’ strategies documented a two-
fold increase in drug loading retuning a 10 versus 20 g of DTXL per 109 DPN, respectively. 
Interestingly, by introducing a simple variation in the fabrication protocol, a two-fold increase in 
drug loading was achieved. Therefore, the additional passages of the polymeric paste over the PVA 
template mainly helped to fill more homogenously the discoidal wells and, thus, increase the 
amount of polymer and drug molecules encapsulated per particle. 
Then, release studies were performed by incubating DTXL- DPN into PBS (infinite sink condition: 
4 liters) up to 72h at pH 7.4 and 6.5, representing the mildly acidic environmental conditions of 
the tumor microenvironment. Figure 3B shows the release curves for the ‘multi-passage’ DTXL-
DPN. Under physiological conditions (pH 7.4), despite a moderate burst within the first few hours 
(30% in 1h), which is most likely related to DTXL molecules adsorbed on the DPN surface, drug 
release appeared to be sustained overtime up to 72h. At 24h, almost 80% of the loaded DTXL was 
released, and this percentage grew to 85% and 90% at 48 and 72h, respectively. As expected, drug 
release was accelerated under acidic conditions for the partial degradation of the DPN matrix 
[125]. Specifically, at pH 6.5, 90% of the drug was released within 24h while it took 72h to 
completely release all loaded DTXL. The ‘multi-passage’, direct loading strategy here 
demonstrated allowed the authors to improve the pharmacological properties of DPNs reaching 
drug loading conditions that are compatible with tumor treatment. However, the ‘multi-passage’ 







Figure 3.3:Pharmacological characterization and in vitro therapeutic properties of DPNs. A. 
Docetaxel (DTXL) amounts and encapsulation efficiencies (EE) for DPNs loaded using the 





over time under physiological (pH 7.4) and acidic (pH 6.5) conditions. C. Cytotoxic potential on 
triple negative breast cancer MDA-MB 231 cells treated with Free DTXL and DTXL-DPNs up to 
72 hrs incubation time (left). Table listing the IC50 values for each treatment condition and time 
point (right). D. Confocal fluorescent microscopy images of untreated (left); Free DTXL treated 
(center); DTXL-DPNs treated MDA-MB 231 cells (20 nM DTXL, at 24h). E. Confocal fluorescent 
microscopy images of MDA-MB 231 cells incubated with DPNs labeled with RhB-DSPE (red) and 
loaded with curcumin (green) at different time point (respectively 4, 8, 24h). 
 
 
Finally, the in vitro cell-killing efficacy of ‘multi-passage’ DPN was tested against a triple negative 
breast cancer cell line, namely the MDA-MB 231 cells. These were incubated with different 
concentrations of DTXL-DPN to estimate the IC50 values at 24, 48 and 72h.  Figure 3C shows the 
percentage of viable cells as a function of free and DPN-loaded DTXL concentrations. As 
expected, DTXL-DPN were less cytotoxic on tumor cells as compared to free DTXL molecules 
for a given time, documenting an IC50 value of 77 ± 1.5 nM against 38.50 ± 3.3 nM at 24h.  
Similarly, at longer time points (72h), the particle formulation confirmed a slightly lower toxicity 
than the free drug with an IC50 value of 7 ± 1.09 nM against 2.6 ± 1.0 nM. Data are presented in 
Figure 3C in graphical and tabular forms. The controlled release of DTXL from the DPN was 
indeed responsible for the lower efficacy of the DTXL-DPN for any given time point. However, 
the cytotoxic potential of free DTXL was essentially preserved upon encapsulation into DPNs. 
Furthermore, the pharmacological activity on cytoskeletal microtubules was assessed by confocal 
microscopy as showed in Figure 3.3 D. The untreated MDA-MB 231 displayed a well-organized 
microtubule cytoskeleton (green) and a typical, elongated shape. On the contrary, cells treated with 
free DTXL and DTXL-DPNs (20 nM) presented microtubule bundles and aberrant mitotic 





used to assess further DPN interaction with MDA-MB 231 at 2, 4, 8, 24h for the concentration of 
10 DPN/cell. Representative images in Figure 3E proved that just a few particles were internalized 
while most DPN sat on or next to the cell membrane releasing thereof the therapeutic cargo. 
3.4.3  Preclinical imaging and therapeutic performance of DTXL-DPN.  
 
To evaluate the in vivo imaging (Cy5-DPN) and therapeutic (DTXL-DPN) performance of the 
discoidal polymeric nanoconstructs, an orthotopic murine model of triple negative breast cancer 
(TBNC) was considered. Figure 3.4 A reports schematically the timeline of the preclinical 
experiment. Initially, MDA-MB-231 luciferin positive cells were injected into the 3rd mammary 
fat pad of 7-weeks old immunodeficient mice and left to proliferate for 45 days to establish a 
palpable tumor mass. Tumor growth was monitored by whole animal optical bioluminescence 
imaging (IVIS) and manually with a caliper. Upon reaching an average tumor size of 0.15 cm3, 
mice were randomly divided in three experimental groups: the ‘saline’ group, including mice 
injected with PBS; the ‘free-DTXL’ group, including mice injected with a DTXL solution (2 
mg/kg); and the ‘DTXL-DPN’ group, including mice treated with 2 mg/kg of DTXL-loaded within 
the DPN. In all the cases, the administration was performed intravenously every 2 days for up to 
30 days, returning a total number of injections equals to 13. Note that the DTXL administered dose 
of 2 mg/kg was significantly lower than that conventionally used in pre-clinical experiments, 











Figure 3.4: In vivo therapeutic and imaging studies on orthotopic breast cancer murine models. 
A. Timeline of the preclinical experiments performed on mice bearing orthotopic breast cancer 
and including bioluminescence/fluorescent imaging and tumor growth analysis. B. Average tumor 
growth curves comparing the efficacy of three different intervention. Data are presented as the 
average tumor volumes ± SD. (black line: saline; red line: Free DTXL; blue line: DTXL-DPN). 
(At 120 days: p < 0.05 for free DTXL vs saline and DTXL-DPNs vs saline; and p = 0.05 for DTXL-
DPNs vs DTXL. At 92 days: p < 0.05 for DTXL-DPNs vs DTXL – n  5). C. Kaplan–Meier curves 
for survival. (black line: saline; red line: free DTXL; blue line: DTXL-DPN). 
 
 
Figure 3.4 B summarizes the tumor growth curves for the three different treatment groups over a 
period of 120 days. Malignant masses in the ‘saline’ group (black line) continuously grew over 





(only 2) were sacrificed. Mice treated with systemically administered free-DTXL (red line) 
showed an initial positive response to therapy with a stabilization of the tumor mass within the 
first 3 weeks of treatment, then followed by a progressive growth demonstrating relapsing of the 
disease. The mice that survived at 120 days (n = 2) showed an average malignant mass of 0.74 ± 
0.57 cm3. The ‘DTXL-DPN’ group (blue line) showed an overall positive response to the treatment 
with a significant tumor stabilization during the whole observation period. As documented in 
Figure 3.4 B, a moderate increase in tumors size was observed during the first 70 days up to an 
average volume of 0.48 ± 0.4 cm3 that was then followed by a steady decrease for the remaining 
observation period below the original tumor size. It was noted that even in the initial phase, the 
tumor growth rate was lower for the mice treated with DTXL-DPN rather than with Free-DTXL. 
Mice survival was plotted in Figure 3.4 C. The three curves demonstrate that 80% of the DTXL-
DPN mice survived at 120 days against the 30% for the case of Free-DTXL. The control mice 
were sacrificed within 90 days because of excessive tumor burden. The difference between average 
tumor volumes for DTXL-DPN and Free-DTXL was statistically significant at day 92 (p = 0.02), 
representing the end point for the saline group, and at day 120 (p = 0.05), indicating the end of the 
study. The average radiance associated with the tumors of the surviving animals at the end of the 
treatment are reported in Figure 3.5, documenting once again the smaller size of the DTXL-DPN 
treated tumors over the Free-DTXL group. Furthermore, to assess any severe toxicity associated 
with the treatment, the mouse weight was monitored for the whole duration of the experiment 
(Figure 3.6). Free-DTXL and DTXL-DPN treatments caused a negligible reduction (10%) in 
mouse weight over the first 20 days. As the treatment was completed, all mice progressively 





point. Overall, the treatment with DPN was well tolerated by the mice and the moderate loss of 
weight should be mostly attributed to the drug inherent toxicity. 
 
Figure 3.5: Tumor size at the end of the treatment. A. Representative images of average radiance 
at the end of the treatments for the three different experimental groups. B. Average radiance of 
the explanted tumors. (Data are plotted as mean radiance ± SD). 
 
Figure 3.6: Body weight curves of the three different experimental groups. (Data are presented 







By loading the near infra-red molecule Cy5 into DPN, the polymeric nanoconstructs were turned 
into theranostic agents, whose accumulation in different organs upon intravenous injection could 
be assessed via whole animal optical imaging (IVIS) [126, 127]. Mice bearing orthotopic breast 
cancers were systemically administered with 109 fluorescent DPN and monitored longitudinally 
by acquiring images at 30 min, 1, 3, 6 and 24h post injection. In the first few hours, fluorescence 
was mostly detected in the abdominal cavity, where almost the totality of the blood is processed 
through the liver. However, the radiance associated with this portion of the animal body was 
observed to continuously reduce over time in favor of a stable tumor accumulation. This was 
documented in Figure 3.7 A where the average normalized radiance in the abdomen and tumor 






Figure 3.7: In vivo therapeutic and imaging studies on orthotopic breast cancer murine models. 
A. Quantification of the average radiance in the tumor tissue and abdominal cavity: identification 
of the Regions of Interest (left); average radiance variation over time within the ROIs (center); 
ratios between the average radiance estimated in the two ROIs over time (right). (Time zero: 
background fluorescence before Cy5-DPNs injections. Data are plotted as mean average radiance 
± SD). B. ex-vivo bioluminescence and fluorescence analysis for main organs (Liver, Spleen, 
Kidneys, Tumor, Lungs) harvested at 24 hrs post Cy5-DPN injection. C. Quantification of the 
average radiance associated with the main harvested organs at 24hrs post Cy5-DPN injection (p 
= 0.02 for Tumor vs Liver; p = 0.009 for Tumor vs Spleen; p = 0.033 for Tumor vs Lungs). 
 
 
This data showed that at time zero the ratio was equal to 1, demonstrating an equal background 
signal in both ROIs (abdomen and tumor) before particle injection. The ratio became lower than 
one in the first few hours, as a consequence of continuous blood processing through the liver and 
other major organs in the abdominal cavity. After the first three hours, the ratio started to steadily 
increase reaching a value of about 1.3 in favor of the tumor at 24 hrs. These observations continued 
to suggest that, at longer time points, DPN would tend to accumulate in the tortuous tumor 
vasculature escaping non-specific sequestration in organs of the Reticulo Endothelial System 
(RES) [128]. Characteristic ex-vivo fluorescent images of different organs, including the tumor 
(112.325 ± 70.5 mg), liver (2292.7 ± 271.5 mg), spleen (145.7 ± 73 mg) and lungs (259.25 ± 99.4 
mg), are assembled in Figure 3.7 B. These confirmed a significant particle accumulation in the 
tumors as opposed to the liver, spleen and lungs, as quantified in the bar chart of Figure 3.7 C. 






The presented results suggested that the combination of a micrometric size with the discoidal shape 
and the overall deformable hydrogel structure allowed DPNs to stay longer in the blood stream. 
Thereby avoided a rapid and massive accumulation in typical RES organs, such as the liver and 
the spleen, and thus increasing the likelihood to deposit with the tortuous vasculature of malignant 
masses [114].  Specifically, the DPN deformability has been shown to play a major role in limiting 
the uptake by phagocytic cells residing in the liver and the spleen (see also Figure 3.3 E), while 
DPN geometry was instrumental in favoring vascular deposition and firm adhesion in tortuous and 
low perfused malignant vessels [118, 122, 129]. Indeed, Figure 3.7 documents a significant 
accumulation of Cy5-DPNs within the tumor tissue. Also, the tumor-to-abdominal cavity 
accumulation appeared to grow monotonously over time to reach a value of 1.3 at 24h post Cy5-
DPN administration (Figure 3.7 A).  
Overall, the high tumor accumulation, low liver sequestration and sustained drug release would 
contribute to explain the efficacy demonstrated by DTXL-DPNs in treating triple negative breast 
cancer. It is important to highlight that animals were injected every 2 days for 13 consecutive times 
with only 2 mg/kg of DTXL. This was sufficient to modulate the growth of orthotopic TNBC 
during the first 70 days and, eventually, induce tumor regression for the following 50 days.  This 
resulted in an 80% survival as compared to 30% for the Free-DTXL treatment. Conventionally, in 
these preclinical studies, DTXL doses ranging between 10 and 50 mg/ kg of animal masses were 
considered [106, 109, 130]. 
Finally, it should be also noted that given the characteristic size of 1,000400 nm, DPNs were not 
expected to cross the fenestrated endothelium and migrate into a perivascular position as most 
nanomedicine do. In this sense, DPNs do not rely on the EPR effect to deposit within malignant 





continue to confirm the importance of bioinspiration and biomimicry in the development of novel 
drug delivery systems [121]. 
 
3.5 CONCLUSIONS 
In conclusions, it has been demonstrated that Discoidal Polymeric Nanoconstructs could be loaded 
with therapeutic and imaging agents to realize a theranostic particle for the treatment of triple 
negative breast cancer. A potent chemotherapeutic agent – docetaxel – and a fluorescent compound 
– Cy5 conjugated to a lipid chain – were efficiently entrapped into the hydrogel matrix of DPNs 
using a ‘multi-passage’ direct loading strategy. Independent of the enhanced permeability and 
retention effect, the geometrical and mechanical attributes of DPNs favored high tumor 
accumulation and supported tumor regression with modest drug doses. These results continued to 
support the notion that effective tumor treatment could be achieved even without relying on the 
EPR effect and, as such, DPNs could be used together with conventional nanomedicines and small 











4 CHAPTER 2: MODULATING THE CHEMICAL PROPRIETIES OF 
DOCETAXEL FOR IMPROVING THE RETENTION WITHIN A 
SOFT PLGA MATRIX 
 
4.1 ABSTRACT  
 
High loading and specific release of therapeutic agents within the tumor microenvironment are 
key factors in the development of novel nano-based therapeutic systems against cancer. Although 
drug availability and preferential tumor accumulation improved with advanced drug delivery 
system for cancer therapy, they still faces challenge in drug encapsulation and retention. Here, 
Discoidal Polymeric Nanoconstructs (DPNs) were employed to load and systemically deliver both 
hydrophilic and hydrophobic therapeutic molecules. DPNs appear as disks, with a diameter of 
about 1 µm and a height of 400 nm, designed for vascular adhesion in a tortuous and low perfused 
vasculature as in the case of tumor. Moreover, soft DPNs presenting a stiffness of about few kPa, 
were shown to circulate longer, more effectively avoid the sequestration by hepatic and splenic 
immune cells and accumulate at higher doses in the tumor vasculature as compared to rigid DPNs.  
DPNs were synthetized by mixing together hydrophobic – poly(lactic-co-glycolic acid) (PLGA) 
and hydrophilic – polyethylene glycol diacrylate (PEG-diacrylate) using a top-down, template-
based fabrication process. Therapeutic molecules were incorporated within the polymer matrix of 
soft DPNs following two different loading approaches: direct loading, where the molecules of 
interest were directly mixed together with the constituting polymers while forming the actual DPN  
matrix; absorption loading, where the molecules of interest was introduced within an already 
formed DPN polymer matrix via capillary suction. In the latter case, DPNs were first lyophilized 





therapeutic molecules that could be dispersed in organic solvents could be incorporated via direct 
loading; whereas, only therapeutic molecules that can be dispersed in water could be incorporated 
via absorption loading.  
Following this notion, two different prodrugs were realized, namely oleic-Docetaxel (O-DTXL) 
and PEG-Docetaxel (PEG-DTXL). O-DTXL was incorporated via both direct and absorption 
loading within the polymeric matrix. Conversely, the more hydrophilic PEG derivatives were 
loaded via absorption. The size and stability of the resulting DPNs were characterized using 
dynamic light scattering. Moreover, electron microscopy (SEM and TEM) were used to 
reconstruct the actual morphology of the particles .The prodrug encapsulation efficiency and 
release kinetics were examined using HPLC. With the absorption loading, it was observed that O-
DTXL formed small micelle-like particles, returning encapsulation efficiencies as high as 13%. 
Differently, free DTXL and O-DTXL loaded directly within the DPN matrix returned low 
encapsulation efficiencies of about 1 and 2%, respectively. The more hydrophilic PEG-DTXL 
were associated with a 15% of encapsulation efficiency. The cytotoxicity of the prodrug-loaded 
DPNs was performed via a conventional MTT assay on MDA-MB-231. In vitro cytotoxicity tests 
confirmed that hydrophilic prodrugs were more efficient than O-DTXL mostly for their faster rate 





Nanostructured polymer particles can be designed and engineered with a wide range of properties 
and can provide new ways to diagnose and treat diseases[131]. In a biological setting, some 





nanostructures play an important role in controlling the in vivo performance and the ability to 
overcome biological barriers to reach the desired site[132, 133]. In this context, human red blood 
cells (RBCs) have largely inspired the nanostructure design and has been even investigated as drug 
delivery tool[134].  For example, Anselmo et al. used the flexibility, circulation and vascular 
mobility of red blood cells (RBCs) to deliver nanoparticles and simultaneously overcome 
biological barriers and coining the term “cellular hitchhiking”. A noncovalent attachment of 
nanoparticles to RBCs simultaneously increases their level in blood over a 24 h period and allows 
transient accumulation in the lungs, while reducing their uptake by liver and spleen. The  flexibility 
is one of the key properties that enables long circulation of RBCs, and the reduced deformability 
is a characteristic of several pathological states[135]. Moreover, as previously demonstrated, 
discoidal nanostructures with micrometric size exhibit deformable proprieties and are able to 
circulate in the bloodstream for a long time[136].  In the last few years, several important steps 
have been made toward engineering soft particles with stealth properties inspired by red blood 
cells [125]. Using mixtures of PEG di-acrylate with poly(lactic-co-glycolic acid) PLGA in 
presence of a photo initiator, a template-based photo polymerization have been used to prepare 
hydrogel particles with tunable elasticity, controlled size and morphology[137]. Such properties 
were achieved by modulating the ratio of PEG di-acrylate and PLGA used for polymeric mixtures 
and have been evaluated atomic force microscopy (AFM)[122]. Although these studies represent 
important advances in bioengineering of the 4S proprieties, the drug loading and retention 
capability of deformable Nano constructs still faces challenges when used to encapsulate small or 
hydrophilic drug entities for therapeutic investigation. In the previous chapter, it was demonstrated 
that a multiple passage approach improved the loading efficiency, retention and stability of the 





Contemporary attempts were focused on optimizing the compatibility between the drug and 
polymers in order to achieve higher encapsulation of the drug.  The prodrug strategy has been 
largely used to overcome multiple barrier such as low solubility, poor stability, lack of cite 
specificity and inefficient cell uptake improving the efficacy of existing anticancer agents.(ref) 
Recently, several prodrug Nano system based on polymer –drug conjugate has been developed 
using block polymers, polyaminoacids, polypeptides or polysaccharides. For example, 
polyprodrug amphiphiles self-assembled from PEG-b-PCPTM was developed for captothecin 
delivery where PCPTM was polymerized with CPT prodrug monomer to achieve a reduction 
responsive drug release. Interestingly, these block polymer can self-assemble in four different 
nanostructures with extremely high CPT loading content of 50%. Furthermore, NKO12, a prodrug 
based nano micelles, with SN-38 conjugated with a PEG-poly(glutamic acid)copolymer, has been 
evaluated in clinical trial.   Different from polymer prodrug, self-assembling small weight prodrugs 
refer to conjugates usually  synthetized by coupling one drug molecules to another small molecules 
such as lipid chains, low molecular weight oligo or amphiphilic peptidic prodrug. Among all, the 
squalene based prodrugs have drawn widespread attention in recent years for displaying high drug 
loading efficiency. Drug molecules with poor water solubility such as Docetaxel or Paclitaxel, 
would certainly benefit from the lipid prodrug strategy for improved lipid solubility and enhanced 
miscibility within the polymer matrix. Ansell et al. reported improved antitumor activity of 
paclitaxel prodrug encapsulated in Nano carriers by manipulating the hydrophobicity of paclitaxel-
lipid alcohol conjugate.(ref) However, the lipid-derivate  suffer from short blood circulation due 
to the lack of  a dense shielding layer. Therefore, usually they were stabilized with PEG chain to 
obtain both long circulation time and high structural stability. Cho et al. pointed out that , since the 





drug delivery approach, could become a prominent trend in both parenteral and non-parenteral 
administration [138].  
 Herein, we engineered a novel class of Discoidal PLGA-PEG-DA Nanoconstructs (DPNs) to 
boost drug loading and release at the targeted site without relying on the EPR effect. Specifically, 
the hydrophobic derivate oleic-docetaxel and the hydrophilic derivative PEG-Docetaxel were 
loaded within the matrix of 1,000400 nm DPNs directly or by absorption of aqueous solution of 
the drug. While the PEG-DTXL was associated with a higher encapsulation efficiency it also 
exhibiter faster release from the particles. The cytotoxicity of the Nanoconstructs was evaluated 
using MTT assay on two cell lines and the tests confirmed that the hydrophilic prodrugs were more 
potent than the hydrophobic counterpart due to their faster rate of release. 
 
4.3 EXPERIMENTAL  
4.3.1 Chemicals  
Polydimethylsiloxane (PDMS) (Sylgard 184) were purchased from Dow Coming Corp (Midland, 
USA). Poly(vinylalcohol) (PVA, Mw 31,000 - 50,000), Poly(DL-lactide-coglycolide) acid 
(PLGA, lactide:glycolide 50:50, Mw 38,000-54,000), Poly(ethylene glycol) diacrylate (Mn 750) 
(PEG diacrylate), 2-Hydroxy-40-(2-hydroxyethoxy)-2-methylpropiophenone (Photo-initiator) 
were purchased from Sigma-Aldrich (Missouri, USA). Docetaxel was purchased from Alfa Easer 
(Massachusetts, USA). 4-(dimethylamino) pyridine (DMAP) (99%), Oleoyl Chloride was 
procured from Sigma Aldrich; Dichloromethane anhydrous ≥99.8%, contains 40-150 ppm 
amylene as stabilizer, Sigma Aldrich; ammine-PEG (1 kDa, 550 Da, 350 Da) creative PEG 





4.3.2 Methods  
 Synthesis of Discoidal polymeric nanoconstructs 
 
 Discoidal polymeric nanoconstructs (DPNs) were synthetized using a top-down fabrication 
strategy described in details in previous works [122, 123]. Briefly, the process involved the use of 
polyvinyl-alcohol template as a hydrophilic molds presenting an ordinate pattern of cylindrical 
wells 1000 x 400 nm that were filled with the polymeric paste. DPNs were synthetized using a 
mixture of poly(lactic acid-co-glycolic acid) (PLGA) and poly(ethylene glycol) diacrylate (PEG 
DA) polymers. 50 mg of PLGA are dissolved in 1 mL of Dichloromethane and mixed with 6 mg 
of PEG-DA and drug. Then, 0.6 mg of a photo-initiator (2-Hydroxy-4’-(2- hydroxyethoxy)-2-
methylpropiophenone) was added into the polymeric solution to allow the crosslinking of PEG 
diacrylate chains after exposure to UV-light (366 nm). A fixed volume of polymeric mixture, 
including docetaxel (5 µL), was then spread through a blade over the PVA template to accurately 
fill each well. Finally, the DPNs were purified by filtration and centrifugation.  
 Loading of Discoidal polymeric nanoconstructs with Drug  
 
Here two different loading approaches were adopted, namely “direct loading” and “absorption 
loading.” In “direct loading,” the Docetaxel prodrugs  were dispersed within the original polymeric 
paste and directly distributed into the wells of the PVA template. In “absorption loading,” the 
collected DPNs were lyophilized to form a powder. This was eventually dispersed in an aqueous 
solution in the case of PEG-docetaxel and methanol solution in the case of oleic-docetaxel . Re-






 Synthesis of oleic-docetaxel prodrug  
 
DTXL (50 mg, 6.19 × 10 -5 mol) and DMAP (12.38× 10 -5 mol) were dissolved in 15 ml of 
anhydrous dichloromethane in a 50 ml round-bottom flask. The regents was stirred for a few 
minutes in nitrogen atmosphere at 0° C. Then oleoyl chloride (14.7 µL) was added dropwise to the 
mixture followed by stirring for 4 h under nitrogen atmosphere and the temperature was 
maintained at 0° C to produce the mono-substituted (2ʹ- oleic-docetaxel). The conjugation of oleic-
docetaxel was monitored by thin layer chromatography (TLC) using dichloromethane: methanol 
(97:3) as solvent. The formation of DTXL conjugate was verified using 1H nuclear magnetic 
resonance (NMR). The reaction mixture was diluted with diethyl ether and washed first with 5% 
HCL and then using brine. The solution of 2ʹ- oleoil-docetaxel was collected and filtered to remove 
the impurities. The product was finally dried with Rotavapor and stored at 0° C. The collected 
solution was dissolved in a minimal amount of dichloromethane and purified using a silica gel 
column with dichloromethane: ethanol (97:3) as mobile phase to obtain the pure conjugate product.  
 Synthesis of Succinic-docetaxel  
 
DTXL (50 mg, 6.19 × 10 -5 mol) and DMAP (12.38× 10 -5 mol) were dried under vacuum for two 
hours before to start the reaction to completely remove trace of humidity. Then, the dried 
compounds were dissolved in 2 ml of anhydrous Pyridine in a 50 ml round-bottom flask. The 
regents was stirred for a few minutes in nitrogen atmosphere at room temperature. Then, succinic 
anhydride dissolved in pyridine (1 eq) was added dropwise and left to react for 4 h under nitrogen 
atmosphere at room temperature to produce the mono-substituted 2ʹ-succinic-docetaxel (2-S-
DTXL). The formation of S-DTXL conjugate was verified using 1H nuclear magnetic resonance 





remove the pyridine and obtain a crystalline powder. The crude compound was dissolved in a 
minimal amount of dichloromethane and purified with automatic silica chromatography using a 
gradient of DCM and DCM: Methanol (9:1) to obtain only the mono-substituted derivate.  The 
purity of the intermediate was investigated using a mass spectrum.  
 Synthesis of PEG 1k-Docetaxel  
 
Purified Succinic- DTXL (50 mg) was dissolved in anhydrous dichloromethane in a 50 ml round-
bottom flask and was activated using EDC (1.2 eq) and NHS (1.2 eq) and TEA for two hours under 
nitrogen atmosphere and room temperature. Then 1 equivalent of amine-PEG 1k was added to the 
reaction mixture and left  overnight.  The reaction mixture was washed with DCM and dried with 
Rotavapor to remove the residual TEA. The crude compound was dissolved in a minimal amount 
of dichloromethane and purified with automatic silica chromatography using a gradient of DCM 
and DCM: Methanol (9:1) to obtain only the mono-substituted derivate.  The purity of the products 
was monitored by NMR and UPLC-MS.  
 Particles size and shape characterization.  
 
The DPN geometry and yielding of the synthesis was assessed using the Multisizer 4E Coulter 
Particle Counter (Beckman Coulter, USA), that calculated particle concentration in a defined 
volume of 20 mL of isotone solution. The hydrodynamic diameter and surface electrostatic charge 
(ζ – potential) of DPN was measured using a Zetasizer Nano (Malvern, UK). The characteristic 
discoidal shape of DPN was confirmed using Electron Microscopy.  DPN morphology was 
observed using a Jem-1011 Transmission Electron Microscope (Jeol, Japan) coated with sputtered 





Fluorescent DPN were synthesized by adding 30 µg of Rhodamin-B (DSPE-RhB) to the polymeric 
mix made of PLGA and PEGDA and were observed using an A1 confocal fluorescent microscope 
(Nikon).  
 
 Chemical characterization  
 
Nuclear magnetic resonance (NMR) spectroscopy. NMR experiment were run on a Burker Avance 
III 400 Systhem (400.13 MHz for 1 H) spectra were acquired using deuterated chloroform (CDCl3) 
as solvent. UPLC –MS analysis were run on waters ACQUITY UPLC-MS system consisting of a 
SQD (single quadrupole detection) mass spectrometer equipped with an electron spray ionization 
interface and a photodiode array detector. The PDA range was 210-400 nm.  
 
 Loading and Release studies.  
 
The ‘direct loading’ method was used to uniformly distribute and load the drug within the DPN 
matrix [123, 124]. Specifically, a 5 µl homogenous drug/polymer solution was uniformly spread 
using a blade over the surface of a 3×3 cm PVA template, containing about 108 wells. On the 
contrary, “absorption loading” has been adopted to concentrate the drugs over the surface of DPN 
that closely interact with the tumor vasculature. In this case, the particles have been synthesized 
using the same procedures of the direct loading but without include the drug in the polymeric 
mixture. Actually, DPN without drugs has been purified and suspended in a small volume of water 
(200 µl), freeze in liquid nitrogen for a few seconds, and readily lyophilized overnight obtaining 





interest. In the case of the hydrophobic Oleic-Docetaxel, the absorption process is divided in two 
consecutive steps. First, 10 µl of the drug solubilized in methanol (5mg/ml) was poured slowly on 
the particles powder then, the resulting solution has been washed with an excess of water (1ml) 
multiples time. In the case of hydrophilic compounds, concentrate water solutions containing the 
drug were used to directly suspend dried particles. Also in this case multiple washes has been 
performed to remove the unloaded drugs.  The amount of drug loaded within DPN was calculated 
using a HPLC and by reading the characteristic docetaxel UV absorbance at 230 nm (Agilent 1260 
Infinity, Germany). Samples for HPLC analysis were prepared by spinning down DPNs at 12,700 
RPM for 20 min, drying the pellet overnight and dissolving the particles upon incubation with 
acetonitrile (ACN). The encapsulation efficiency was calculated considering the percentage weight 
ratio between the drug amount loaded within the DPN matrix at the end of the synthesis process 
and the initial drug input. Release studies were performed in a volume of 4L of buffer at controlled 
pH 7.4 and 37° C to reproduce typical physiological conditions. At each time point, 200 µL of 
DPN solution was poured into Slide-A-Lyzer MINI dialysis cups with a molecular cut off of 10 
kDa (Thermo Scientific) and dialyzed. At each time point, DPNs were collected and dissolved in 
ACN to read the amount of DTXL entrapped in the matrix overtime.  
 In vitro cell viability tests. 
 
 For cytotoxicity tests in vitro, the human Triple Negative Breast Cancer cell line MDA-MB231 
was obtained from the American Type Culture Collection (ATCC). Cells were cultured in Eagle's 
minimal essential medium (EMEM) (ATCC, USA) completed with 10% FBS (Gibco, Thermo 
Fisher Scientific, USA), 1% penicillin/streptomycin (Sigma-Aldrich, USA), under a humid 





the reduction of MTT (3-(4,5-dimethylthiazolyl)-2,5- diphenyltetrazolium bromide) (Sigma-
Aldrich, USA) by mitochondrial dehydrogenase to blue formazan product. This reflects the normal 
function of mitochondria and, hence cell viability. Briefly, different number of cells were seeded 
in 96-well plates for each time point, in the specific 104 cells/well for the 24h, 7.5x103 for 48h, 
and 5 x103 for 72h were seeded in 96-well plates and incubated at 37°C, 5% CO2, for 24 h. The 
day after, cells were treated with EMEM containing the selected doses of DTXL, O-DTXL and 
PEG-DTXL (0.1 – 1,000 nM).  After 24, 48 and 72 h, the treatment solution was removed and 
replaced by MTT solutions, according to the manufacturer’s instructions. The resulting formazan 
crystals were then dissolved in ethanol (200 μL/well) and the absorbance was recorded at 570 nm 
using a microplate reader (Tecan, CH). Six replicates were considered for each DTXL 
concentration. Data were collected when the absorbance ranged between 0.8 and 1.2. Cell viability 
was normalized to that of untreated cells. 
 
4.4 RESULTS AND DISCUSSION 
4.4.1 Synthesis of Discoidal polymeric nanoconstructs  
 
The synthesis of discoidal particles comprises of a number of sequential steps as previously 
described in chapter 1. In this way, the morphological and mechanical proprieties were precisely 
controlled in order to optimize their in vitro and in vivo performance.  
After drying the PVA template, its wells were accurately filled by uniformly spreading a polymeric 
paste. This comprised of an homogeneous mixture of the hydrophobic poly(D,L-lactide-co-
glycolide)-acid carboxylic terminated (PLGA-COOH) and hydrophilic poly(ethylene glycol) 





and PEG-DA mixture formed the actual polymeric matrix of DPN, which was characterized by 
hydrophobic and hydrophilic pockets entrapping the loaded agents. In the current configuration, 
highly hydrophobic drug oleic docetaxel (O-DTXL) was dispersed within the polymer matrix. 
Following the absorption loading method, empty particles were lyophilized and re-dispersed in a 
water solution containing the hydrophilic derivate (Figure 4.1).  To release and collect the DPNs 
empty or loaded with the drug, the PVA templates were dissolved in water for 3 hours at room 
temperature under gentle stirring.  
 
 
Figure 4.1: Description of two different approach of loading either hydrophilic or hydrophobic 





4.4.2 Characterization of Docetaxel conjugates  
The ability to synthesize and evaluate polymer-drug conjugate libraries in which molecular mass, 
architecture and linker chemistry are varied is crucial step to develop promising therapeutic 
candidates. It was challenging to understand specific physicochemical properties of the final NPs 
to one singular element in the design of the conjugate. Here, has been applied the structure-activity 
relationship (SAR) approach that has been routinely practiced for small molecule drugs to develop 
optimal polymer-drug conjugate. In this pilot study, we investigated how the PEG molecular 
weight could affect the physicochemical properties in vitro and in vivo efficacy and toxicity of the 
resulting conjugates. 
 
In this study, Docetaxel was mono substituted with oleic moieties using an efficient method that 
produced the docetaxel conjugate in high yield. The oleoyl acid-chloride group of was directly 
conjugated to the hydroxyl group (OH) group of docetaxel in a single step. Site- specific 
conjugation of the fatty acid moieties to the OH group of DTXL was achieved by variation of the 
temperature during the reaction procedure. The conjugation of the fatty acid moieties was 
confirmed by 1H-NMR as reported in Figure 4.2. The chemical shifts for the hydroxyl hydrogens 
at the C2’ (OH-C2’) position 3.35 ppm disappear following conjugation. Furthermore, the 1H 
chemical shift for the hydrogens connected to C2’ (HC-2’) 4.62 ppm resonated at lower field 
strengths due to the conjugation showing a shift in the peak to 5.45 ppm. As previously reported, 
following this protocol the mono-substitution of Docetaxel was favored in the more reactive C2’ 














Figure 4.2: Chemical characterization of modified Docetaxel. 1H NMR spectra of oleic docetaxel 





4.4.3 Loading of Docetaxel prodrug into Discoidal polymeric nanoconstructs  
 
The dispersion of therapeutic molecules within the polymeric structure of DPNs was achieved 
following two different strategies: a “direct method,” where the agent was dissolved in the organic 
solvent and directly mixed with the PLGA, PEG and PI paste prior to deposition over the PVA 
template.  Instead in the “absorption method,” the agent was dispersed in a high concentration in 
water, which was then exposed to the lyophilized powder of DPNs.  In direct loading, the agent 
had to be soluble and stable in an organic solvent whereas, for the absorption method, the agent 
had to be soluble in water at high concentrations without forming micellar structures. The direct 
loading was used for the highly hydrophobic derivate oleic docetaxel (Figure 4.1).  
In general, “direct loading” is the most straightforward procedure. The main requirement for the 
agent to be “directly loaded” is its solubility and stability in organic solvents, like dichloromethane 
(DCM), chloroform (CHCl3) or acetonitrile (ACN). The compound was directly mixed with the 
original polymeric paste forming the DPNs and applied over the PVA template. A drawback of 
this loading procedure was the low encapsulation efficiency (EE), which was related to the yielding 
in the preparation of the DPNs, the characteristic soft polymeric matrix of DPNs and the chemical 
proprieties of the loaded agent.  As per the yielding, it was noted that a portion of the loaded agent 
and polymeric paste are wasted during the deposition onto the PVA wells. Moreover, using a small 
volume of polymeric solution in organic solvent (5ul in DCM) to save the chemotherapic agent 
and materials, this procedure favored the faster evaporation of the solvent making the spreading 
of the solution over the wells difficult. As per the chemical proprieties, hydrophilic compounds 
(lower LogP) possessed a tendency to rapidly escape the DPN polymeric matrix during the 





Therefore, the hydrophobic compound oleic-docetaxel was selected to be tested after direct loading 
in DPNs. Oleic acid has been extensively used to modify the chemical proprieties of docetaxel and 
increase the compatibility of the drug with delivery system[139]. The conjugation of oleic acid 
with Docetaxel should have increased the Hydrophobicity and consequently the affinity for the 
DPN polymeric matrix. However, a morphological analysis of the particles performed by electron 
transmission microscopy (TEM) after O-DTXL direct loading showed that the hydrophobic 
prodrug was poorly compatible with the polymeric interior and even less with the water exterior 
causing aggregation events within the particles (Figure4.3). In the same fashion, as shown in 
Figure 3, when O-DTXL was adsorbed on DPNs, it formed self-assembled nano-spheres around 
100nm that fused with the DPNs.   
“Absorption loading” consisted of exposing a concentrated solution of the agent to lyophilized 
DPNs. For O-DTXL, the first step of the absorption included the exposition of freeze-dried 
particles to a concentrated methanol solution of the prodrug followed by several wash of the 
particles suspension in water to remove unloaded drugs. After the first interaction between the 
prodrug and the particles in methanol solution, the re-hydration phase caused a self-assembling of 
the prodrug, resulting in fusion of the spheres on the surface of DPNs.  Interestingly, lipid prodrugs 
with higher lipophilic character and decreased water solubility easily precipitated in water in form 
of spheres. This was due to the shift of crystallinity in favor of amorphous state as compared with 
free Docetaxel. For derivate PEG1k-DTXL, given the hydrophilicity, only the absorption loading 
was performed using a water solution of the prodrug. In this case, dried DPNs avidly absorbed 
water into their polymeric structure, which was enriched with the molecules of the agent to be 
loaded. To be noted that a fine balance between compound hydrophilicity and hydrophobicity was 







Figure 4.3: Morphological characterization DPN direct loaded with oleic-Docetaxel. Images by 
Scanning electron microscopy (left) and transmission electron microscopy (right) of DPNs with 
oleic docetaxel direct loaded (top panel) and self-assembling structures of oleic docetaxel by water 
precipitation.  
4.4.4 Encapsulation and release profile of prodrug loaded in DPNs  
 
Based on the above reasoning, the encapsulation efficiency (EE) into the DPNs would vary for 
each considered prodrug and loading strategy. By direct loading the hydrophobic derivate showed 
improved encapsulation efficiency up to 2% compared with only 1 % of the free drug. The 
comparison between the TEM images in Figure 4.3 with the results in Figure 4.4 C, clearly showed 





was mostly related to the prodrug aggregates rather than the increased affinity for the polymer. 
Indeed the aggregate formation suggested that the oleic docetaxel was not properly soluble in 
PLGA but preferred to self-aggregate.   
Figure 4.4: Morphological and pharmaceutical characterization of DPNs loaded with oleic-
docetaxel. A) SEM images after O-DTXL absorption; B) Dynamic light scattering of purified 
DPNs (light blue) and O-DTXL Nano spheres; C) Encapsulation efficiency (EE%); D) release 
profile.  
 
By “absorption loading”, the particles were dissolved in methanol solution and then they were 







characteristic morphology evaluated by SEM (Figure 4.4 A) and size evaluated by DLS (Figure 
4.4 B). Moreover, extra wash was essential to remove the unloaded drugs as observed from the 
DLS analysis of the supernatant after centrifugation of the DPNs (Figure 4.4 B). Following this 
approach the encapsulation increased to even more up to 13%. Interestingly, the lipid prodrugs 
with higher lipophilic character and decreased water solubility could easily precipitate in water in 
the form of spheres due to the drop of crystallinity in favor of amorphous state as compared with 
free Docetaxel [96]. Despite these promising results, in terms of drug loading, the release of O-
DTXL after absorption was too slow with a profile very similar to the O-DTXL loaded by direct 
method both not optimal for tumor treatment (Figure 4.4 D). These results suggested that O-DTXL 
is too hydrophobic to be released efficiently. 
Consequently, to modulate the release profile, the synthesis of a water soluble derivate using PEG 
with amine termination was investigated.  PEG-Docetaxel prodrug was synthesized starting from 
succinic-docetaxel intermediate. In fact its carboxylic termination was easily reacted with PEG 
functionalized with amine group in presence of coupling reagent such as EDC/NHS and TEA, to 
form the expected product.   Given the high hydrophilicity, PEG-Docetaxel was loaded, at the 
beginning, only by using the above-mentioned absorption method, specifically by suspending 
dried particles on a PEG-DTXL solution. Data reported in Figure 4.5 showed an encapsulation 
efficiency comparable with O-DTXL. This confirmed that DPNs were able to capture both 
hydrophilic and hydrophobic derivate after absorption. These results were very promising showing 
the possibility to produce docetaxel derivatives to enhance the loading efficiency of DPNs.  
However, since most of the PEG-Docetaxel was absorbed on the surface and given its high 





directly loaded DTXL. Therefore, there is need of fine tuning the affinity of the prodrug for the 
polymeric matrix to control more precisely the release rate in vitro.  
 
Figure 4.5: Morphological and pharmaceutical characterization of DPNs loaded with PEG1k-
docetaxel. A) SEM images after PEG1k-DTXL absorption; B) Encapsulation efficiency (EE%); 
C) release profile at 37° C and pH 7.4  D)  Cytotoxicity in vitro on MDA-MB 231 cell line  
 
4.4.5 Cell Viability Studies for the Prodrugs  
 
MTT tests were performed to assess the therapeutic efficacy of prodrugs as compared to the free 
compound.  Specifically, MDA-MB231 breast cancer cells were incubated with increasing 
concentration of free DTXL, O-DTXL and PEG1k-DTXL. Results depicted in Figure 4.5 clearly 
showed the cytotoxic properties of free DTXL  where the IC50 was evaluated to be equal to 25 nM 
after 72hrs. On the other hand, cell viability upon O-DTXL treatment was not significantly affected 
even at the higher doses. These result may be ascribed to the ester bond connecting DTXL to the 






lipid chain. Since O-DTXL was released very slowly, the therapeutic efficacy of the prodrug would 
be reached only at much longer incubation time. 
On the contrary, the therapeutic efficacy of the hydrophilic prodrug  PEG1k-DTXL reported in 
green bar chart,  deftly showed that the conjugation of docetaxel with hydrophilic chain to be 
slightly more effective  on MDA-MB 231. When compared with hydrophobic derivate the 
therapeutic effect was dependent on the hydrolysis of the parental drug and not on the 
concentration of the drug in the treatment. Finally, PEG modification slightly improved the 
pharmacological proprieties of Docetaxel conjugate but future studies were needed to find the right 




Two different loading strategies were documented to encapsulate hydrophobic and hydrophilic 
therapeutic compounds within the polymeric matrix of Discoidal Polymeric Nanoconstructs 
(DPNs). The hydrophobicity/hydrophilicity ratio of Docetaxel were modulated by conjugating it 
directly with lipid (oleic acid) and polymeric chains (PEG 1 kDa). In the “direct loading” method, 
the compounds were first dissolved in the polymeric paste forming the DPNs and then applied to 
the PVA template. This approach suffered from the current sub-optimal fabrication yielding of 
DPNs returning encapsulation efficiencies roughly of 1% for Docetaxel. When the highly 
hydrophobic prodrug oleic-docetaxel were loaded directly within the DPNs, the percentage of 
encapsulation increased up to 2% due to phenomena of aggregation. In the “absorption method,” 
the compounds were suspended in methanol (for hydrophobic prodrug) or in water (for hydrophilic 
prodrug) using high concentrations and dragged inside the polymeric matrix of DPNs upon 





hydrophilicity and returned encapsulation efficiencies roughly of 13% and 15 % respectively.   
These two features were also shown to affect the release profiles of the loaded compounds. In 
general, direct loading was associated with lower release rates as compared to absorption loading 
for a given compound. This was ascribed to the fact that the compounds in the absorption loading 
were mostly confined in the vicinity of the DPN surface and were therefore more rapidly released 
into the surrounding aqueous environment. Differently, in direct loading, the compounds were 
uniformly distributed within the polymeric matrix. As expected, a delay was documented in the 
cytotoxic activity in vitro mostly due to the esterification of the parental drug and the therapeutic 
effect strongly depended on the hydrolysis rate that clearly was more favored for the hydrophilic 
derivate such as PEG1k-DTXL.  Collectively, these results demonstrated that the properties of 
DPNs could be finely tuned during the fabrication process by changing the loading strategies 
(direct vs. absorption) and compound properties (hydrophobicity and molecular weight). Future 
studies will focus more on further optimizing the loading and release conditions and pre-clinically 















5 Chapter 3: Soft Discoidal polymeric Nanoconstructs 
delivering PEG-Docetaxel prodrug for the treatment of 
Glioblastoma multiforme  
 
 
5.1 ABSTRACT  
 
Glioma is recognized as the most aggressive and fatal form of brain cancer. Current therapeutic 
approaches for glioma consist of surgery and chemotherapy, but they have a poor rate of success. 
They are associated with major drawbacks such as invasiveness of the intracranial surgical 
procedure and poor brain tumor accumulation of the anticancer drugs. Conventional nanoparticles 
have been explored for their potential of increasing the distribution of chemotherapeutic agents in 
systemic tumors. In the present work, soft Discoidal Polymeric Nanocontructs without further 
modifications, have been prepared and tested as nanocarriers for the delivery of PEG-Docetaxel 
Prodrug to human glioblastoma cells (U87). For achieving a better loading efficiency and drug 
stability within the soft DPN matrix, the Hydrophobic Docetaxel was covalently linked to an 
hydrophilic portion of Poly-(ethylene)glycol and was included in the formulation to form a 
prodrug-encapsulated complex within the hydrophilic pockets of DPN. In particular, PEG550 was 
used for the reaction with Docetaxel activated with a succinic linker.  In the current configuration, 
DPNs loaded with DTXL-PEG550 exhibited better pharmaceutical behavior in terms of 
encapsulation, release rate and therapeutic efficacy in vitro as reported in previous chapter. The 
advantage of using the DPNs as a delivery tool for hydrophilic prodrug was primarily to protect 
the prodrug from Esterase hydrolysis, confirmed by the higher IC50 reported for the MTT test 





cells but localized very close to cells where they released the drug overtime and the delayed 
efficacy in vitro was ascribed to the higher stabilization of the drug within DPNs. Although the 
lower efficacy of PEG550-Docetaxel DPN in vitro compared with Docetaxel and PEG550-
Docetaxel, the systemic treatment of DPNs loaded with PEG550-DTXL have showed an increased 
therapeutic efficacy in glioblastoma in vivo model using a very low doses of 1 mg/kg. Thus, the 
present work demonstrated the feasibility of using soft DPN as a tool to control the relapse of 
GBM after tumor resection.  
.  
5.2 INTRODUCTION  
 
Glioblastoma multiforme (GBM) is considered as the most aggressive form of gliomas tumor and 
encompass the 80% of all primary brain tumor in adults [140, 141].  The current WHO 
classification of gliomas includes GBM in the grade IV subtype for the high rate of proliferation 
and infiltration in the neighboring tissue causing the worst clinical outcome.  After diagnosis the 
patients show a mean survival of 15 months and only 5% survive more than 5 years despite the 
use of aggressive therapies [142, 143]. Although the limitation associated with the location of the 
disease and its complex biology, current treatment includes surgical resection followed by 
radiation and chemotherapy using cytotoxic agents. For the surgery, the major complication 
observed is the difficulties related the complete removal of the malignant mass due to the absence 
of sharpened confinement and an amenable site reveling in all cases a high probability of 
recurrence [144].  
In addition to the multiple obstacles ascribed with systemic delivery of cytotoxic agents into the 





major obstacle. Upon systemic administration, very low concentration of drugs were actually 
delivered in tissue surrounding the tumor even in the case of active agents for glioma therapy [145, 
146].  GBM is typically characterized by a damaged tumor neovasculature (TBB) due to the high 
grade of proliferation, other factor such as the size of the molecules, the lipophilicity and the 
presence of active efflux pumps influenced the drug entry into the central nervous system [147].  
Temozolomide (TMZ) is the first agent in 20 years approved by the FDA to treat glioblastoma and 
has been one of the most commonly used anti-glioma agents with limited adverse effects due to 
its ability to penetrating the blood brain barrier (BBB)[148].  Despite the multi modal invasive 
treatment, just few patients survive beyond 5 years and it is mostly related to drug resistance 
developed by the tumor cells [149]. However, other potent drugs acting on cell cycle disruption 
as Docetaxel (DTXL) has been tested in various tumors. Docetaxel is currently used as first-line 
therapy for patients with breast cancer and non-small cell lung carcinoma. Furthermore, it was 
reported that DTXL presented a good apoptosis-inducing effect even for glioblastoma cells in 
vitro. However it’s in vivo efficacy was highly compromised due to extensive efflux by p-gp 
present in the brain endothelial cells, hydrophobicity and dose-limiting toxicity [150]. To 
overcome these physicochemical limitations and to increase the site-specific activity, several 
efforts has been focused on the chemical modification, for example, the conjugation of 
chemotherapeutic drugs with polyethylene glycol (PEG), known as PEGylation [151]. Beyond the 
advantage of increasing circulation kinetics by extending residence time in the blood and human 
safety, administrating PEGylated cytotoxic drugs instead of the free drugs could lead to the 
possibility of by-passing drug efflux, mediated by P-glycoproteins (P-gps)[91, 152].  
Here we tested the Discoidal Polymeric Nanoconstructs (DPNs) that intrinsically target the 





PEG550-DTXL prodrug. The presence of PEG-prodrug with a sufficiently short length favored the 
longer circulation of the drug and increased the in vivo efficacy.  
 
5.3 EXPERIMENTAL  
5.3.1 Chemicals  
Polydimethylsiloxane (PDMS) (Sylgard 184) were purchased from Dow Coming Corp (Midland, 
USA). Poly(vinylalcohol) (PVA, Mw 31,000 - 50,000), Poly(DL-lactide-coglycolide) acid 
(PLGA, lactide:glycolide 50:50, Mw 38,000-54,000), Poly(ethylene glycol) diacrylate (Mn 750) 
(PEG diacrylate), 2-Hydroxy-40-(2-hydroxyethoxy)-2-methylpropiophenone (Photo-initiator) 
were purchased from Sigma-Aldrich (Missouri, USA). Docetaxel was purchased from Alfa Easer 
(Massachusetts, USA). 4-(dimethylamino) pyridine (DMAP) (99%) Sigma Aldrich; 
Dichloromethane anhydrous ≥99.8%, contains 40-150 ppm amylene as stabilizer, Sigma Aldrich; 
ammine-PEG 550 Da creative PEGworks. 
5.3.2 Methods  
 Synthesis of Discoidal polymeric nanoconstructs 
Discoidal polymeric nanoconstructs (DPNs) were synthetized using a top-down fabrication 
strategy described in details in previous works [122, 123]. Briefly, the process involved the use of 
polyvinyl-alcohol template as a hydrophilic molds presenting an ordinate pattern of cylindrical 
wells 1000 x 400 nm that were filled with the polymeric paste. DPN were synthetized using a 
mixture of poly(lactic acid-co-glycolic acid) (PLGA) and poly(ethylene glycol) diacrylate (PEG 
DA) polymers. 50 mg of PLGA was dissolved in 1 mL of Dichloromethane and mixed with 6 mg 





methylpropiophenone) was added into the polymeric solution to allow the crosslinking of PEG 
diacrylate chains after exposure to UV-light (366 nm). A fixed volume of polymeric mixture, 
including PEG550-DTXL (5 µL), was then spread through a blade over the PVA template to 
accurately fill each well. Finally, the DPNs were purified by filtration and centrifugation.  
 
 Synthesis of PEG 550-Docetaxel  
 
Succinic- DTX was synthesized and purified as described in the previous chapter. Pure succinic-
docetaxel (50 mg) was dissolved in anhydrous dichloromethane in a 50 ml round-bottom flask and 
was activated using EDC (1.2 eq) and NHS (1.2 eq) and TEA for two hours under nitrogen 
atmosphere at room temperature. Then 1 equivalent of amine-PEG 550 Da was added into the 
reaction mixture and the reaction was left overnight.  The reaction mixture was washed with DCM 
and dried with Rotavapor to remove residual TEA. The crude compound was dissolved in a 
minimal amount of dichloromethane and purified with automatic silica chromatography using a 
gradient of DCM and DCM: Methanol (9:1) to obtain only the mono-substituted derivate.  The 
purity of the product was monitored by NMR and UPLC-MS.  
 Particles size and shape characterization. 
 
The DPN geometry and yielding of the synthesis was assessed through Multisizer 4E Coulter 
Particle Counter (Beckman Coulter, USA), that calculated particle concentration in a defined 
volume of 20 mL of isotone solution. The hydrodynamic diameter and surface electrostatic charge 





discoidal shape of DPN was confirmed using Electron Microscopy.  DPN morphology was 
observed using Scanning Electron Microscopy (Helios Nanolab 650) after 10 nm aureum coating.  
 
 Chemical characterization  
 
Nuclear magnetic resonance (NMR) spectroscopy. NMR experiment were run on a Burker Avance 
III 400 Systhem (400.13 MHz for 1 H). Spectra were acquired using deuterated chloroform 
(CDCl3) as solvent. UPLC –MS analysis were run on waters ACQUITY UPLC-MS system 
consisting of a SQD (single quadrupole detenction) mass spectrometer equipped with an electron 
spray ionization interface and a photodiode array detector. The PDA range was 210-400 nm. 
 Loading and Release studies.  
 
The direct loading method was used to uniformly incorporate PEG550-DTXL derivate within the 
DPN matrix [123, 124]. Specifically, a 5µl homogenous drug/polymer solution was uniformly 
spread using a blade over the surface of a 33 cm PVA template, containing about 108 wells. The 
amount of drug loaded within the DPN was calculated using a HPLC and by reading the 
characteristic docetaxel UV absorbance at 230 nm (Agilent 1260 Infinity, Germany). Samples for 
HPLC analysis were prepared by spinning down DPN at 12,700 RPM for 20 min, drying the pellet 
overnight and dissolving the particles upon incubation with acetonitrile (ACN). The encapsulation 
efficiency was calculated considering the percentage weight ratio between the drug amount loaded 
within the DPN matrix at the end of the synthesis process and the initial drug input. Release studies 
were performed in a volume of 4L of buffer at controlled pH 7.4 and 37° C to reproduce typical 





Lyzer MINI dialysis cups with a molecular cut off of 10 kDa (Thermo Scientific) and dialyzed. At 
each time point, DPN were collected and dissolved in ACN to read the amount of DTXL entrapped 
in the matrix overtime.  
 In vitro cell viability tests. 
 
For cytotoxicity tests in vitro, the human glioblastoma cell line U87-MG was obtained from the 
American Type Culture Collection (ATCC). Cells were cultured in Eagle's minimal essential 
medium (EMEM) (ATCC, USA) completed with 10% FBS (Gibco, Thermo Fisher Scientific, 
USA), 1% penicillin/streptomycin (Sigma-Aldrich, USA), under a humid atmosphere (37°C, 5% 
CO2, 95% air). Cell viability was determined by MTT assay, which detected the reduction of MTT 
(3-(4,5-dimethylthiazolyl)-2,5- diphenyltetrazolium bromide) (Sigma-Aldrich, USA) by 
mitochondrial dehydrogenase to blue formazan product. This reflected the normal function of 
mitochondria and, hence cell viability. Briefly, different number of cells were seeded in 96-well 
plates for each time point, in the specific 104 cells/well for the 24h, 7.5x103 for 48h, and 5 x103 
for 72h were seeded in 96-well plates and incubated at 37°C, 5% CO2, for 24 h. The day after, 
cells were treated with EMEM containing the selected doses of PEG550-DTXL (1 – 1,000 nM).  
After 24, 48, 72, and 96h the treatment solution was removed and replaced by MTT solutions, 
according to the manufacturer’s instructions. The resulting formazan crystals were then dissolved 
in ethanol (200 μL/well) and the absorbance was read at 570 nm using a microplate reader (Tecan, 
CH). Six replicates were considered for each drug concentration. Data were collected when the 






 Tumor model and therapeutic experiments. 
 
 All animal experiments were performed according to the guidelines established by the European 
Communities Council Directive (Directive 2010/63/EU of 22 September 2010) and approved by 
the National Council on Animal Care of the Italian Ministry of Health. All efforts were made to 
minimize animal suffering and use the lowest possible number of animals required to produce 
statistical relevant results, according to the “3Rs concept”. For the orthotopic intracranial GBM 
tumor model, 5-6 week old female athymic nude mice were stereotactically inoculated with 
U87MG luciferin positive cells (Charles River, Calco, Italy). Animals were grouped in ventilated 
cages and able to freely access food and water. They were maintained under controlled conditions: 
temperature (21 ± 2 °C), humidity (50 ± 10%) and light (12 and 12 h of light and dark, 
respectively). Before cells injection, animals were anaesthetized with a mixture of ketamine (10%) 
and xylazine (5%), which was administered via a single intraperitoneal injection. For the injection, 
trypsinized  5x105 U-87MG luciferase positive cells were resuspended in cold phosphate-buffered 
saline. A total of 3 ul of PBS was injected into the right hemisphere of the mouse brain (1.5 mm 
posterior to the bregma, 1.4 mm lateral to the midline, and 1 mm depth from skull, at a speed of 
0.3 μL/min using a 10 μL sterile Hamilton syringe fitted with a 26-gauge needle attached to a 
stereotaxic frame. Wounds were closed with sterile wound clips and animals were carefully 
monitored until recovered from anesthesia. Tumor growth was followed by IVIS every 2 day, upon 
intraperitoneal injection of D-luciferin, Potassium salt (GoldBio) at a dose of 150mg/Kg. At day 
15, before starting the treatments, a bigger hole of about 3 mm was created in the same stereotactic 
coordinates by using a Trephine - 2.7mm Diameter. The more superficial part of the tumor was 
resected by using a scalpel. The skull was then sealed by a drop of silicon elastomer.  IVIS was  





in three experimental groups: saline, free TMZ  and PEGDtxlDPNs, were intravenously injected 
at a dose of 1mg/Kg every other day. The effectiveness of the different treatments was valued by 
optical imaging (IVIS) every two days. All mice were euthanized when they became moribund. 
Survival was monitored and plotted using the Kaplan-Meier method. Log-rank test was used to 
test the significance of different survival curves.  
5.4 RESULTS AND DISCUSSION 
5.4.1 Synthesis and Characterization of Docetaxel conjugates  
 
As a large number of novel polymeric-drug vehicles are being developed, the ability to robustly 
synthesize and evaluate polymer-drug conjugate libraries in which molecular mass, architecture 
and linker chemistry are varied is increasingly valuable to develop promising therapeutic 
candidates. Here, we have employed the SAR approach that has been routinely practiced for small 
molecule drugs to develop optimal polymer-drug conjugate delivery systems. In this pilot study, 
we investigated how the PEG molecular weight could affect the physicochemical properties and 
in vitro and in vivo efficacy of the resulting conjugates. Based on the previous study, here we 
evaluated the effect of a short molecular weight PEG and tested the hypothesis that SAR must be 
performed to develop the optimal conjugates. To effectively generate only the mono-substituted 
conjugates and simultaneously limit other variables, we employed two-step reaction to 
functionalize short-chain mPEG-NH2 with Docetaxel. Firstly, to prepare the suggested PEG550-
DTXL conjugates, the intermediate Succinic-docetaxel (S-DTXL) was synthesized according to 
Figure 5.1 A. The exact mass of Docetaxel mono-functionalization with succinic acid was 
confirmed by mass spectra as showed in Figure 5.1 B. Automatic silica-chromatography 







Figure 5.1: Chemical characterization of Succinic-Docetaxel. A) Scheme of reaction for 
succinic-Docetaxel; B) reaction control by TLC (right) and UPLC-MS; C) Nuclear magnetic 









































1H-NMR, reporting the characteristic shift of the 1H signal at 4.6 ppm (Figure 5.1 C). To link the 
PEG-amine with S-DTXL, the coupling reagents EDC and NHS were used to activate the carboxyl 
group of S-DTXL and accelerate the reaction (Figure 5.2 A). Mass spectra was employed to 
monitor the reaction end point and purification of m-PEG-Docetaxel conjugate reported in Figure 
5.2 B. Furthermore confirmation of the reaction were achieve by 2D-HSCQ spectra confirming the 
formation of amidic bond with the signal of -CH2NHCO- (3.40, 39.8 ppm) (Figure5.2 C).  
and accelerate the reaction (Figure 5.2 A). Mass spectra was employed to monitor the reaction end 
and purification of m-PEG-Docetaxel conjugate as reported in Figure 5.2 B. furthermore 
confirmation of the reaction were achieve by 2D-HSCQ spectra confirming the formation of 









Figure 5.2: Chemical characterization of PEG550-Docetaxel. A) Scheme of reaction for PEG550-
Docetaxel; B) mass spectra obtained by UPLC-MS; C) Nuclear magnetic resonance 









5.4.2 Loading of Docetaxel prodrug into Discoidal polymeric nanoconstructs  
 
We hypothesized that the functionalization of Docetaxel with short m-PEG chain like PEG550 Da 
stabilized the drug within the hydrophilic pocket of the soft matrix of DPNs owing to non-covalent 
chemical interactions between similar polymers and waters (i.e. hydrogen bond). Instead, as 
reported in previous work, self-aggregations events were recorded by using longer PEG 
lengths[153].  So far, modified drug was consistently loaded into DPNs to improve the 
encapsulation efficiency following two loading strategies [123]. Direct loading was preferred to 
uniformly disperse and slowly release the hydrophobic drug. Whereas, absorption was preferred 
for hydrophilic drug displaying a faster release in comparison within the first hours upon systemic 
injection. Therefore, the two strategies were selected based on the drug and the application of 




Figure 5.3: DPNs morphological characterization. A) size distribution of DPNs loaded with 
PEG550-DTXL and zeta-potential (B) measured by Dynamic Light Scattering (DLS). C) 







Given the solubility of the PEG derivate in DCM, the prodrug was loaded directly to achieve a 
slow and controlled release that, together with the prolonged circulation of DPNs, allowed to 
display a longer availability of the treatment over time. DPNs after loading with PEG550-DTXL 
maintained the characteristic size distribution around 1100 nm as reported in Figure 5.3 A. This 
data confirmed the versatility of the synthesis process that allowed direct encapsulation of 
hydrophilic compounds without affecting the physiochemical proprieties. Moreover, the negative 
zeta potential around -27 mV was preserved although the direct loading of the drug, ensuring the 
stability of the suspension. Effectively, the presence of the PEGylated prodrug could be 
appreciated in Figure 5.3 B acquired with electron scanning microscopy. After drug loading by 
top-down approach, most of the drug should be displayed on the surface or at the interface with 
the water. Indeed, it was possible to appreciate from the image that the particles presented a sort 













5.4.3 Pharmacological proprieties of PEG550-DTXL prodrug loaded in DPNs  
 
The amount of drug encapsulated and release profile over time were presented in Figure 5.4 A as 
derived by high performance liquid chromatography (HPLC). A direct comparison between the 
Docetaxel and PEG550-Docetaxel strategies documented a two-fold increase in drug loading 
retuning a 10 versus 20 g of DTXL per 109 DPN, respectively. Interestingly, the introduction of 
a short PEG chain favor the retention of the drug within the matrix.  
Then, release studies were performed by incubating PEG550-DTXL DPN and DTXL DPN into PBS 
(infinite sink condition: 4 liters) up to 72h at pH 7.4 and both profile are showed in Figure 5.4 B. 
Under physiological conditions, the characteristic burst release within the first hour, which was 
most likely related to molecules at the interface of polymer-water, reach 40% for Docetaxel and 
near 20% for PEG550-DTXL. At 24h, almost 70% of the loaded DTXL was released against the 
60% for the conjugate and this percentage increased in the following hours arriving up to 80% and 
70% respectively. Together these results, confirmed our hypothesis that the conjugation with PEG 
stabilized the drug within the polymeric nanostructures by chemical interactions.  
Figure 5.4: Pharmacological characterization.  A. Docetaxel (DTXL) amounts for DPNs loaded 
using the ‘Docetaxel’ vs the ‘PEG550-Docetaxel’ strategy. B. Docetaxel (green) and PEG550-






5.4.4 Cell Viability Studies for PEG550-DTXL and preliminary in vivo study  
 
Finally, the pharmacological activity of the prodrug was tested against glioblastoma cell line (U87-
MG) that were incubated with increasing concentration of DTXL, S-DTXL and PEG550-DTXL.  
 In general, the treatment with PEG550-DTXL was associated with delayed response as compared 
with free drug. Specifically, at 24 h IC50 increased from 52 nM for DTXL to 75 n M for prodrug. 
However, this difference became negligible at 96h showing a comparable value of 6 nM and 8 nM 
respectively. As documented in the previous study the conjugation with polymeric or lipid chains 
had a considerable effect on the pharmacological activity of the drug that should be ascribed to the 
rate of hydrolysis of the new bond. As showed in the table in Figure 5.5, in the case of S-DTXL 
treatment the IC50 value was much higher compared to the other treatment, reporting a value of 52 
nM at 96h. These results suggested that the esterification of Docetaxel with short PEG could be 
the right hydrophobicity-hydrophilicity balance to maintaining the pharmacological proprieties of 
the drug.  
Preliminary studies in vivo were conducted on glioblastoma tumor model. In the present study, the 
treatment with DPNs was evaluated after surgical removal of tumor mass after 15 days from U87-
MG injection into the brain. In the preliminary pilot study, the treatment was conducted with a 
very low dose of 1 mg/kg every other day. As reported in Figures 5.6 the treatment with 
PEG550DTXL-DPNs was more effective compared to TMZ administrated intravenously at doses 
of 3 mg/kg. Overall, this data are still insufficient to demonstrate the preferential accumulation of 
the soft particles into the brain. Therefore, currently studies are ongoing to increase the group size 






 Figure 5.5: In vitro therapeutic properties of PEG550-DTXL. Cytotoxic potential on 
Glioblastoma multiform cancer U87-MB cells treated with Free DTXL (green), SUCCINIC-
DTXL (grey) and  PEG550-DTXL (orange)  up to 96 hrs incubation time (bar chart)  . Table listing 












In this work it was demonstrated that the conjugation of docetaxel with hydrophilic polymer chains 
of PEG improved the favorable interaction with the polymer backbone of the nanostructures 
obtained by mold-fabrication and the encapsulation efficiency increased. This resulted controlled 
release of the drug with a decreased burst of the 20% in the first hour. Furthermore, the 
manipulation of Docetaxel with short PEG resulted in a similar pharmacological efficacy in vitro 
in comparison with unmodified Taxol. Significant improvement was observed when the prodrug 
loaded DPNs were tested in preclinical model of glioblastoma in vivo compared with the currently 
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